Intel uvedl, že vyšší než očekávané tržby Xeonů byly taženy poptávkou hyperscalerů po host CPU pro AI servery. To naznačuje, že AI přináší firmě růst i mimo Gaudi.
SUQIAN, CHINA - JUNE 1, 2026 - A netizen is using his mobilephone to view intel logo and using his computer to view intel webpage in Suqian, Jiangsu, China on June 1, 2026. (Photo credit should read CFOTO/Future Publishing via Getty Images)
CFOTO/Future Publishing via Getty Images
This article was written by Doug Nathman, with research by his team at Trefis.
Underlying the semiconductor manufacturer's rising stock price was a story that went unnoticed: the subtle yet significant revival of its oldest and most powerful product.
As we approached mid-2025, it was understandable to think that Intel (INTC) might be a value trap on its path to becoming an artifact of the past. Based on its fiscal Q1 2025 outcomes, the firm's trailing twelve-month revenues declined by 4.0% compared to the previous year, and it was facing a profoundly negative net margin of -36%. The figures were dismal enough to spark entire discussions about the margin squeeze jeopardizing Intel stock. The options market was lackadaisical, with implied volatility residing in the calm 35th percentile of its annual spectrum just weeks before the surge commenced.
By all indications, this was not a stock poised for a 369% increase.
What Was Being Overlooked By The Market?A portion of the narrative was a classic diversion. All attention was directed towards Intel's initiative to develop a specialized AI accelerator chip, Gaudi, to rival industry leaders. The news, however, on that front was disappointing. In late 2024, the management acknowledged that the adoption of Gaudi was "slower than we anticipated" and that it would fall short of its revenue goals. By early 2025, the company disclosed its decision to cancel the next-generation version, an internal venture, as a marketable product. For those monitoring Intel’s direct challenge in the AI training sector, the situation appeared to be a setback.
Yet this narrative missed the company's fundamental strength.
What Was Management Indicating Regarding Its Core CPU Division?While the Gaudi narrative faltered, another, more impactful one was gaining momentum in the background, frequently during the same earnings calls. Management began to subtly yet consistently discuss the changing landscape of AI. They asserted that the dialogue was transitioning from merely training models to effectively utilizing them for inference, a workload where the traditional server CPU, the Xeon, held a pivotal role.
As early as October 2024, the CEO proclaimed that this solidified Intel's status as the 'preferred head node in AI servers,' emphasizing that as the industry progressed toward inference, it would rely on workloads that were 'far more CPU-centric.' By January 2025, his successor underscored the company’s "leading position as the host CPU for AI servers" and the "substantial opportunity for CPU-based inference." The argument was evident: the impending wave of AI would generate tremendous demand for CPUs alongside GPUs.
When Did This Narrative Begin To Appear In The Financial Outcomes?A compelling story is one aspect; actual figures are another. The final indication came in April 2025, coinciding with the company's fiscal Q1 results. The report itself was mixed, but the specifics were revealing. The CFO had achieved figures at the upper end of their guidance, explicitly stating that it was "driven by better-than-expected Xeon sales."
What fueled this strength? He indicated it was "driven by hyperscaler demand for host CPUs for AI servers." The understated narrative had finally made its way to the income statement. DCAI revenue, the segment encompassing those chips, exceeded expectations. It marked the first concrete indication that the increasing significance of the CPU in the AI epoch was a real, revenue-generating phenomenon.
The indicator was not in a flashy new offering, but in the market rediscovering how indispensable Intel’s oldest product line was to the latest technological trend.
And if it is broad exposure to semiconductors you seek, rather than pursuing the next single entity to surge, a semiconductor ETF like SOXX encompasses that entire sector.
Recognizing a setup prior to its rise is a genuine advantage, yet a stock you are enthusiastic about can easily become an oversized portion of your portfolio, and the same volatility that fuels a surge can also reverse it. Concentration can convert that downturn into significant losses, and selling to reduce it incurs a tax liability. There exists a method to secure the profits and diversify without the tax implications.
Pfizer má v indexu S&P 500 nejvyšší dividendový výnos 7,1 %, což vyvolává obavy o jeho udržitelnost. V prvním čtvrtletí činil zředěný zisk na akcii 0,47 USD při dividendě 0,43 USD.
A high-yielding dividend may sound great for investors, but it can be a double-edged sword: when it's too high, investors start to worry about its safety. That's a big part of the reason why Pfizer (PFE 0.90%), whose 7.1% yield is well above the S&P 500 average of just 1.1%, isn't able to draw in investors; many are worried the dividend is due for a cut.
Not only is Pfizer's dividend far above average, but it is now also the highest yield in the entire S&P 500. Is this a warning sign for investors that the dividend may be cut in the near future, or could Pfizer prove to be an underrated income stock to buy right now?
Image source: Getty Images.
Pfizer's yield has been volatile in recent years A high yield can be concerning, but that alone doesn't make it risky. Similarly, just because a yield is low doesn't mean it's sustainable, either. The yield can fluctuate significantly because it is tied to the share price. When a stock is rising, its yield falls because it costs more to secure the same level of dividend income. And when it falls, as has been the case with Pfizer's stock in recent years, the yield can rise significantly.
PFE Dividend Yield data by YCharts
If Pfizer posts strong earnings numbers in its upcoming quarterly results, issues promising guidance, or there's positive news around one of its drugs, its share price could take off, and just like that, the yield could come down.
There is, however, some risk with the dividend because Pfizer's earnings haven't been all that strong in recent quarters. During the first three months of the year, the company's diluted per-share profit was $0.47, not much higher than its quarterly dividend rate -- $0.43. There's not much of a buffer there, and investors may also be concerned about its long-term future, as the pharma company deals with patent cliffs and navigates a challenging course ahead, which could see its sales (and profits) drop in the future.
Today's Change
(
-0.90
%) $
-0.22
Current Price
$
24.26
Is Pfizer's stock worth buying? Pfizer's dividend may look shaky, but the good news is the company's earnings aren't in bad shape, and it's in the midst of restructuring and cutting costs, which should give it more breathing room in the future. It has also acquired companies that could unlock more growth opportunities down the road.
While this may not be the type of stock investors can simply buy and forget, Pfizer may be a good option for income investors willing to monitor it closely. As of now, the dividend still looks safe, and this could be an underrated option to consider, especially given its low valuation, as the stock trades at just eight times its estimated future earnings, based on analyst expectations.
Pfizer čeká, že růst onkologických tržeb ve 2. čtvrtletí podpoří Padcev, Lorbrena, Braftovi-Mektovi kombinace, Elrexfio a biosimilars, zatímco Ibrance a Adcetris budou dál klesat. Firma má také přinést aktualizace k pozdním onkologickým kandidátům a PF-08634404.
Key Takeaways Pfizer's Q2 oncology sales may be lifted by Padcev, Lorbrena, Elrexfio and oncology biosimilars. PFE is expected to share updates on late-stage oncology candidates and PF-08634404 on its Q2 call. Ibrance and Adcetris declines may be offset by stronger sales from newer cancer therapies. Pfizer (PFE - Free Report) is one of the world’s leading oncology drugmakers, with a strong presence across breast, genitourinary, thoracic, gastrointestinal and hematologic cancers. The company has built a broad portfolio of marketed cancer therapies and maintains a deep oncology pipeline spanning multiple treatment modalities, including small molecules, antibody-drug conjugates (ADCs) and immuno-oncology biologics.
Oncology sales comprise around 27% of its total revenues. Its oncology revenues grew 7% to $3.8 billion in the first quarter of 2026. Investors will be keen to know how its oncology segment performed in the second quarter when the company announces results on Aug. 4.
Pfizer’s oncology sales in the second quarter are expected to have been driven by higher sales of key drugs like Padcev, Lorbrena and the Braftovi-Mektovi combination, which should make up for declining sales of drugs like Ibrance and Adcetris. Sales of the new drug, Elrexfio, are also likely to have risen in the quarter.
The Zacks Consensus Estimate for Padcev is $661 million, while that for Ibrance is $1.05 billion.
Pfizer has ventured into the oncology biosimilars space and markets six biosimilars for cancer. Its oncology biosimilars are expected to have made a significant contribution to sales growth in the second quarter of 2026, similar to the past few quarters.
Pfizer is also likely to provide updates on its key oncology candidates on the second-quarter conference call. Several oncology candidates have entered late-stage development, such as atirmociclib and sigvotatug vedotin. A regulatory application seeking approval of sasanlimab is also under review in the EU.
Last year, Pfizer entered into a global ex-China in-licensing agreement with China's 3SBio for exclusive rights to PF-08634404, a dual PD-1 and VEGF inhibitor, which it plans to establish as a potential backbone therapy across multiple tumor types. Pfizer plans to start four pivotal studies for PF-08634404 in 2026. An update on PF-08634404 is expected on the second-quarter conference call.
Competition in the Oncology SpacePfizer is one of the largest drugmakers of cancer medicines. Other large players in the oncology space are AstraZeneca (AZN - Free Report) , Merck (MRK - Free Report) , J&J (JNJ - Free Report) and Bristol-Myers.
For J&J, the Oncology segment comprises around 29% of total revenues and 45% of its Innovative Medicine segment sales. Its oncology sales rose 17.8% on an operational basis in the first quarter of 2026, driven by strong market growth and share gains of key cancer products such as Darzalex and Erleada. The sales growth was partially dampened by lower sales of Imbruvica. J&J’s new cancer drugs, Carvykti, Tecvayli, Talvey and Rybrevant/Lazcluze, are contributing significantly to top-line growth, driven by market share gains.
For AstraZeneca, oncology sales now comprise around 45% of total revenues. Sales in its oncology segment rose 16% at constant exchange rate (CER) in the first quarter of 2026. AstraZeneca’s strong oncology performance was driven by medicines such as Tagrisso, Lynparza, Imfinzi, Calquence and Enhertu (in partnership with Daiichi Sankyo).
Merck’s key oncology medicines are PD-L1 inhibitor, Keytruda and PARP inhibitor, Lynparza, which it markets in partnership with AstraZeneca. Keytruda, approved for several types of cancer, alone accounts for around 50% of Merck’s pharmaceutical sales. Keytruda recorded sales of $8 billion in the first quarter of 2026, up 8% year over year.
PFE’s Price Performance, Valuation and EstimatesPfizer’s stock has risen 1.6% so far this year compared with an increase of 12.1% for the industry.
Image Source: Zacks Investment Research
From a valuation standpoint, Pfizer appears attractive relative to the industry and is trading below its five-year mean. Going by the price/earnings ratio, Pfizer’s shares currently trade at 8.42 forward earnings, significantly lower than 18.49 for the industry as well as the stock’s five-year mean of 9.37.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2026 earnings has declined from $2.99 per share to $2.96 per share, while that for 2027 has been stable at $2.86 per share over the past 60 days.
Image Source: Zacks Investment Research
Pfizer has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Shares of IBM were down more than 23% when the market opened on Tuesday, raising fresh questions about whether companies are seeing enough near-term returns from artificial intelligence spending.
It is shaping up to be the worst day for IBM in decades, as its second-quarter earnings results showed profit and revenue missed analysts' forecasts.
In a letter to investors on Tuesday, CEO Arvind Krishna said IBM's Z mainframe business — its large enterprise computing systems boasting advanced AI capabilities — lagged behind the company’s outlook. The flagship product is the z17, described as a "transaction processing powerhouse."
"Given this was the strongest start to a mainframe program in our history, we expected Infrastructure revenue to decline low-single digits for the year, beginning this quarter," Krishna wrote. "What played out was worse than our expectations, driven by a shortfall in our Z performance and the associated software stack, primarily in Transaction Processing."
IBM CEO WARNS WASHINGTON MUST FIND ‘GOLDILOCKS’ MIDDLE GROUND ON AI REGULATIONS
IBM CEO Arvind Krishna attends an event in the Rose Garden of the White House in Washington, D.C., on July 6, 2026. (Mandel Ngan/AFP via Getty Images)
The IBM z17 is a mainframe that has been pitched as something that can instantly detect fraud when a customer swipes their credit card.
"Every time you swipe your credit card, check your bank balance, make a stock transaction or use an ATM, that transaction is likely running through an IBM Z. With AI embedded directly on the platform, IBM’s new z17… enables clients to detect fraud in real time without moving their data," according to IBM's website.
Krishna said IBM's shortfall was largely caused by weakness in this software and infrastructure business as clients prioritized spending on hardware to insulate themselves from further price jumps.
The IBM Watson IoT Center is located in the Highlight Towers in Munich, Germany, on May 22, 2026. (Michael Nguyen/NurPhoto via Getty Images)
IBM'S NEW AI TOOL LETS MASTERS FANS SEARCH OVER 50 YEARS OF TOURNAMENT HISTORY
"In the last few weeks of June, we saw clients shift their quarterly capex spend toward servers, storage, and memory purchases to secure supply-constrained infrastructure ahead of expected price increases," Krishna wrote.
"This dynamic impacted client buying patterns. While we anticipated some supply chain related impact in our expectations, we did not anticipate the magnitude of the capex reprioritization," he continued.
IBM posted adjusted earnings of $2.93 per share on $17.2 billion in revenue, missing Wall Street estimates of $3.01 per share and $17.86 billion in revenue, according to CNBC.
In this photo illustration, the IBM logo is seen displayed on a smartphone. (Mateusz Slodkowski/SOPA Images/LightRocket via Getty Images)
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
Maria Bartiromo, host of FOX Business' "Mornings with Maria," pointed out on Tuesday that IBM's slide is having a ripple effect on the tech sector.
"The biggest drag on the Dow Industrials this morning is IBM. This is the worst day so far that we've ever seen for IBM," Bartiromo said. "This unexpected warning this morning sent a shockwave through the tech sector, causing software names to sell off; ServiceNow, Salesforce, Microsoft, all down."
Other tech firms trading lower this morning include Arm Holdings, Oracle, and Apple.
Phillips 66 těží z levné ropy z Permské pánve a Kanady, což podporuje rafinérské marže a dlouhodobý růst zisku i cash flow. Firma cílí na kontrolovatelné náklady 5,50 USD za barel.
Key Takeaways Phillips 66 leverages access to low-cost crude from the Permian Basin, Canada and other regions.Phillips 66 targets controllable costs of $5.50 per barrel to further optimize refining margins.Rising Canadian crude supply and global fuel demand support PSX's long-term earnings and cash flow growth. The refineries of Phillips 66 (PSX - Free Report) are connected to the Permian Basin, Canada and other key production regions, ensuring access to competitively priced feedstocks. Its strategically located refineries serve both domestic and export markets, enabling the company to capitalize on strong product demand. Consequently, PSX is well-positioned to maximize refining margins through its integrated network and access to low-cost crude.
Phillips 66 has maintained crude utilization rates above industry averages for three years and consistently delivered an 87% clean product yield. The company's refineries process a high proportion of medium and heavy crudes, while retaining feedstock flexibility to exploit widening price differentials. By targeting adjusted controllable costs of $5.50 per barrel, management aims to drive margin optimization. Every $1 improvement in refining market indicators could generate $700 million in incremental EBITDA for PSX.
Favorable macroeconomic trends support PSX’s long-term financial performance. Canada's crude production is projected to rise steadily through 2030, providing a larger, more reliable supply of affordable feedstock. Simultaneously, global transportation fuel demand, led by jet fuel, diesel and gasoline, is expected to increase from 1.3 million barrels per day in 2027 to 2.4 million barrels per day by 2030. Together, abundant North American supplies and rising fuel demand will boost refinery utilization, strengthen refining margins, and drive long-term earnings and cash flow growth for Phillips 66.
VLO & MPC Gain From Favorable Refining Fundamentals
Beside Phillips 66, several U.S. refiners like Valero Energy Corporation (VLO - Free Report) and Marathon Petroleum Corporation (MPC - Free Report) are also benefiting from favorable refining fundamentals and are expected to remain well-positioned over the next few years.
Valero operates 14 high-complexity refineries with approximately 3 million barrels per day of throughput capacity. The leading refiner benefits from its highly complex Gulf Coast refineries and strong export capabilities. VLO reaches consumers through a robust retail footprint of around 7,000 branded outlets.
Marathon Petroleum benefits from its integrated refining and midstream network, which includes 16 refineries located across the West Coast, Gulf Coast and Mid-Continent regions of the United States. The company has a combined crude processing capacity of about 3 million barrels per day. In the first quarter of 2026, MPC’s refining flexibility and high utilization rates unlocked stronger refining profits.
PSX’s Price Performance, Valuation & EstimatesPhillips 66 shares have gained 53.7% over the past year compared with the industry’s 41.1% growth.
Image Source: Zacks Investment Research
From a valuation standpoint, PSX trades at a trailing 12-month enterprise-value-to-EBITDA (EV/EBITDA) of 13.84X. This is above the broader industry average of 5.73X.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for PSX's second-quarter 2026 earnings and 2026 earnings has seen upward revisions over the past seven days. Meanwhile, estimates for third-quarter 2026 have seen upward revisions.
Image Source: Zacks Investment Research
PSX currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
T-Mobile US čelí obavám trhu ze satelitů, ale zůstává chráněný díky 5G, přímé dohodě se SpaceX a schválené výměně licencí s Grain Management. Bank of America ho navíc zvýšila na Buy s cílovou cenou 220 USD.
Institutional capital is gripped by a narrative that space-based internet will dismantle traditional telecommunications. Low-Earth-orbit satellite constellations, championed by SpaceX's NASDAQ: SPCX Starlink, are being rapidly deployed, prompting analysts to cut their ratings and price targets for legacy carriers. The sheer speed of the Starlink launch schedule creates an illusion that ground-based networks will soon be obsolete.
The market is treating this shift as a systemic threat to all broadband and wireless operators, punishing the telecom sector indiscriminately. However, fear often outpaces logic, creating pockets of opportunity for investors willing to examine the actual science behind network infrastructure.
Get T-Mobile US alerts:
Grounded Reality: Separating 5G Fact From Space FictionT-Mobile US Today
$187.89 -0.52 (-0.27%)
As of 12:19 PM Eastern
This is a fair market value price provided by Massive. Learn more.
52-Week Range$165.66▼
$261.56Dividend Yield2.17%
P/E Ratio19.97
Price Target$255.76
Lumping a pure-play wireless operator like T-Mobile US NASDAQ: TMUS into the same risk category as legacy wireline and cable operators reveals a fundamental mispricing.
While dying wireline infrastructure faces genuine existential pressure from satellite alternatives, terrestrial 5G networks operate on entirely different physical and economic realities.
T-Mobile does not carry the burden of decaying copper phone lines or unprofitable media spin-offs.
The current technical weakness in the telecom sector provides a window to evaluate T-Mobile as an asset generating robust free cash flow while the broader market remains distracted by satellite hype.
Expanding the Signal: Spectrum Swaps and Direct-to-Device DealsThink about the physics of data transmission. Low-Earth orbit satellites provide an excellent solution for rural bandwidth gaps, offering connectivity where laying fiber is economically unviable. However, these satellites lack the localized infrastructure to handle the concentrated data consumption of high-density metropolitan areas. The physics of latency and bandwidth make satellite internet a non-threat to urban 5G networks.
T-Mobile commands an untouchable mid-band 5G spectrum moat that easily handles the density of urban data consumption. The Federal Communications Commission recently approved T-Mobile's authorization to exchange 800 MHz licenses for 600 MHz spectrum with Grain Management. This swap fortifies the firm's low-band coverage, which is critical because low-frequency signals travel further and penetrate thick concrete buildings in cities with far greater efficiency. This allows T-Mobile to expand its rural footprint and reinforce urban density without demanding new capital expenditures.
Positioning Starlink solely as a competitor also misrepresents T-Mobile's strategic positioning. The company maintains a direct-to-device partnership with SpaceX. This alliance inherently hedges the disruption risk that exposes AT&T NYSE: T and Verizon NYSE: VZ. By integrating satellite connectivity to eliminate dead zones for existing mobile customers, T-Mobile is co-opting the technology rather than fighting it.
Ground Troops: T-Mobile's Strategic B2B AssaultConsumer wireless is a saturated, highly competitive market. For years, T-Mobile operated as a loss leader, using aggressive keep-and-switch promotions to steal market share from the legacy duopoly. The network advantage is now sustaining organic retention, allowing management to quietly implement restrictions on those expensive consumer acquisition offers. The focus has shifted from subscriber land grabs toward expanding average revenue per user and protecting operating margins.
To find the next leg of heavy growth, T-Mobile is pivoting aggressively toward enterprise clients. The recent appointment of Chris Sambar as Chief Enterprise Officer illustrates this ambition. Sambar replaces veteran executive Mike Katz, bringing a specific and dangerous pedigree to the role. Having architected AT&T's FirstNet and scaled enterprise B2B sales, Sambar's arrival signals a direct assault on the lucrative corporate connectivity and Internet of Things total addressable market. T-Mobile wants to power fleet tracking, smart cities, and automated manufacturing hubs.
To support this enterprise push, the board elevated Chief Technology Officer John Saw to oversee a newly integrated unit combining engineering, IT, and cybersecurity. Consolidating infrastructure command under a single leader minimizes operational bloat and streamlines deployments ahead of capital expenditure cycles for artificial intelligence and the new 6G spectrum. Enterprise clients demand rigorous cybersecurity integration alongside their connectivity, and this internal restructuring aligns with the requirements of high-margin corporate contracts.
Gravity-Defying Margins: Arbitrage in a Panicked SectorThe broad satellite panic recently prompted Bernstein to issue downgrades and price target cuts across the entire telecom space, citing subscriber cannibalization. Conversely, Bank of America upgraded T-Mobile from Neutral to Buy and set a new $220 price target, which represents a more than 15% profit gap from current trading levels.
Current Price$188.00High Forecast$310.00Average Forecast$255.76Low Forecast$170.00T-Mobile US Stock Forecast Details
Morgan Stanley explicitly noted that T-Mobile's back-book pricing remains roughly 10% below peers, while slightly adjusting its price target to $230.
The back-book pricing metric shows that T-Mobile still has a vital cushion. At 10% below its peers, it can raise prices on legacy plans to drive revenue growth while reducing the risk of customer churn to competitors.
T-Mobile's underlying financial health supports a premium valuation. The company delivered Q1 2026 quarterly earnings of $2.27 per share, beating consensus estimates by 26 cents, alongside aggressive top-line revenue growth of 10.6% year over year.
T-Mobile trades at a trailing price-to-earnings ratio of 2, with a forward multiple compressing to about 18.
A PEG ratio of 1.11 indicates that earnings growth is largely keeping pace with valuation premiums.
Profitability ratios demonstrate remarkable operational efficiency for a capital-intensive business, marked by a return on equity of 19.47% and a net margin of 11.65%. T-Mobile also yields a 2.2% dividend, comfortably supported by $22.46 per share in cash flow.
Investors should always weigh the realities of the balance sheet. Telecom operators carry heavy leverage, and T-Mobile is no exception, sporting a debt-to-equity ratio of 1.58. A quick ratio of 0.97 indicates that liquid assets closely match short-term obligations. While T-Mobile is positioned far better than peers burdened by aging copper lines, its capital structure requires flawless execution in a higher-for-longer interest rate environment.
Staying Grounded: Capitalizing on Misguided Orbital FearsThe market often struggles to separate sector threats from idiosyncratic strengths. Low-Earth orbit broadband will certainly alter the economics of rural internet service providers and legacy wireline companies. However, it is not likely to replace the terrestrial 5G infrastructure required to power mobile devices and enterprise networks in major economic hubs.
T-Mobile is leveraging strategic spectrum swaps, a direct SpaceX partnership, and key executive poaching to aggressively capture B2B market share. Generating $88.31 billion in annual sales with accelerating post-paid phone adds, T-Mobile is operating from a position of profound strength. Investors seeking to capitalize on unwarranted sector sympathy might view the current $188 price level as a discounted entry point for this structurally insulated wireless operator ahead of the July 23 earnings report.
Should You Invest $1,000 in T-Mobile US Right Now?Before you consider T-Mobile US, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and T-Mobile US wasn't on the list.
While T-Mobile US currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.
Clorox těží z růstu v segmentu Household, kde PURE a Scentiva překonaly očekávání a firma získává podíl na trhu. Slabší vývoj v segmentech Litter a Food ale brzdí celkový růst.
Key Takeaways Clorox's Cleaning business is gaining share as PURE and Scentiva launches beat expectations.Litter packaging, pricing and shelf-placement changes are slowing recovery despite distribution gains.ERP completion, shelf resets and pricing actions are expected to improve execution across the portfolio. The Clorox Company's (CLX - Free Report) Household segment remains its biggest source of stability, but recent commentary suggests that strength in one business alone may not be enough to drive broader growth. While the segment continues to benefit from solid demand in cleaning products and successful innovation, weakness in a few other categories is weighing on the company's overall momentum.
Management highlighted that the Cleaning business is the portfolio's standout performer. Product launches, including the Clorox PURE allergen platform and additions to the Scentiva lineup, are gaining shelf space, generating strong early consumer response and outperforming internal expectations. Despite an intensely promotional environment, the company has said that it continues to gain market share in cleaning, reinforcing the strength of its flagship brands.
However, the positive momentum in Household is being offset elsewhere. Fresh Step cat litter remains in the middle of a multi-year transformation, with new packaging, product claims and pricing architecture creating temporary disruption. Although distribution gains have met expectations, shelf placement issues and the complexity of converting shoppers to new products have slowed the recovery. Management also acknowledged that Food categories remain under pressure from elevated promotions and weaker-than-expected category demand.
Clorox believes execution rather than demand is the key variable. With the ERP rollout completed, management expects better service levels, stronger on-shelf execution and faster commercialization of innovation. Retail distribution points increased more than 5% in the third quarter of fiscal 2026, while additional shelf resets are expected through the fourth quarter. The company is also expanding revenue growth management initiatives, targeted pricing actions and brand investments to strengthen value perception.
The Household segment provides an important foundation, but Clorox's ability to sustain long-term growth will ultimately depend on whether improvements in Litter, Food and other businesses can match the momentum already visible in Cleaning.
CLX’s Price Performance, Valuation & EstimatesShares of the Zacks Rank #4 (Sell) company have lost 7.6% in the past three months against the industry’s growth of 5%.
Image Source: Zacks Investment Research
From a valuation standpoint, CLX trades at a forward price-to-earnings ratio of 15.66X compared with the industry’s average of 17.59X.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for CLX’s fiscal 2026 earnings implies a year-over-year decline of 27.3%, while that of fiscal 2027 shows growth of 11.5%. The company’s EPS estimate for fiscal 2026 has been unchanged in the past 30 days.
Image Source: Zacks Investment Research
Stocks to Consider in the Consumer Staples SpaceUnited Natural Foods (UNFI - Free Report) is the leading distributor of natural, organic and specialty food and non-food products in the United States and Canada. The company currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for United Natural Foods’ current financial-year EPS indicates growth of a whopping 254.9% from the prior-year reported level. UNFI delivered a trailing four-quarter earnings surprise of 29.9%, on average.
Church & Dwight Co. Inc. (CHD - Free Report) develops, manufactures and markets a broad range of household, personal care and specialty products. The company currently has a Zacks Rank of 2 (Buy).
The Zacks Consensus Estimate for CHD’s 2026 EPS indicates growth of 6.2% from the previous year’s reported figure. Church & Dwight delivered a trailing four-quarter average earnings surprise of 6.5%.
Krispy Kreme (DNUT - Free Report) operates as a branded retailer and wholesaler of doughnuts, coffee and other complementary beverages and treats and packaged sweets. The company currently carries a Zacks Rank of 2.
The Zacks Consensus Estimate for Krispy Kreme’s current financial-year EPS indicates growth of 30% from the year-ago reported number. DNUT delivered a trailing four-quarter negative earnings surprise of 6.3%, on average.
Fastly se připojila k DIMPACT jako první poskytovatel edge cloudu, aby zlepšila měření digitálních emisí. Firma také uvedla výhled tržeb na 170–176 milionů USD a non-GAAP EPS 5–8 centů pro 2. čtvrtletí 2026.
Key Takeaways Fastly joined DIMPACT as its first edge cloud provider to improve digital emissions measurement. Fastly's platform data and sustainability dashboard help customers track electricity use and emissions. Fastly projects Q2 2026 revenues of $170-$176 million and non-GAAP EPS of 5 cents to 8 cents. Fastly (FSLY - Free Report) shares have surged 96.8% in the year-to-date period, significantly outperforming the Zacks Computer and Technology sector’s 17.0% gain. The rally reflects improving financial performance, accelerating security revenue growth and growing adoption of the company's edge cloud platform.
Fastly is strengthening its long-term growth prospects by expanding its digital sustainability initiatives. As global internet traffic and artificial intelligence (AI) workloads continue to rise, enterprises are increasingly seeking infrastructure providers that not only deliver high performance but also help measure and reduce the environmental impact of digital operations.
Fastly Expands Digital Sustainability Through DIMPACTFastly joined DIMPACT, a leading collaboration focused on measuring and reducing the carbon footprint of digital media. As the first edge cloud platform provider to participate in the initiative, Fastly will contribute edge network expertise, emissions data and technical insights to help develop more accurate methodologies for measuring emissions across digital content delivery.
The partnership is expected to benefit media companies, streaming providers, publishers and other digital businesses by improving visibility into emissions generated throughout the internet delivery chain. As organizations place greater emphasis on Scope 3 emissions reporting and sustainability goals, Fastly's participation could strengthen its relationships with enterprise customers seeking environmentally responsible infrastructure partners.
This integration of Fastly's global edge platform data with DIMPACT's sustainability framework is expected to help customers optimize digital delivery, reduce environmental impact and strengthen Fastly's position as a trusted infrastructure provider.
Sustainability Initiatives Strengthen Fastly's Growth StoryFastly's participation in DIMPACT leverages the scale of its global edge cloud platform, which processes more than 5 trillion requests daily across 578 terabits per second of edge capacity. The company can provide real-world operational data that helps enterprises better measure and manage the environmental impact of digital content delivery as customer traffic flows through its infrastructure before reaching end users.
FSLY offers a sustainability dashboard that tracks electricity consumption and greenhouse gas emissions associated with platform usage, complementing DIMPACT's goal of establishing industry standards for digital emissions. These capabilities could strengthen Fastly's relationships with multinational streaming, publishing and enterprise customers seeking both high-performance edge services and greater carbon transparency.
The initiative also supports Fastly's international expansion strategy, particularly as sustainability reporting requirements continue to evolve globally. The company continues to expand its presence in Asia-Pacific, including a new Singapore office, while positioning sustainability and carbon transparency as differentiators for enterprise customers. Its improving execution is reflected in first-quarter 2026 revenue growth of 20% to $173 million, 47% growth in security revenues and a 63% increase in remaining performance obligations to $369 million.
Fastly Offers Strong Q2 2026 OutlookFastly's expanding AI, security and edge cloud platform, together with improving enterprise demand, are expected to support revenue growth.
For the second quarter of 2026, FSLY guided revenues to $170-$176 million and non-GAAP earnings to 5-8 cents per share.
The Zacks Consensus Estimate for second-quarter 2026 revenues is pegged at $174.03 million, indicating year-over-year growth of approximately 17.02%.
The consensus mark for second-quarter 2026 earnings is pegged at 7 cents per share, which has remained unchanged over the past 30 days, indicating year-over-year growth of 333.33%.
FSLY's Zacks Rank & Stocks to ConsiderCurrently, Fastly carries a Zacks Rank #3 (Hold).
Digital Turbine (APPS - Free Report) , Dell Technologies (DELL - Free Report) and Analog Devices (ADI - Free Report) are some top-ranked stocks that investors can consider in the broader Zacks Computer and Technology sector. Digital Turbine, Dell Technologies and Analog Devices sport a Zacks Rank #1 (Strong Buy) each at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
APPS shares have rallied 99% in the year-to-date period. The long-term earnings growth rate for Digital Turbine is pegged at 18.98%.
DELL shares have surged 239.3% in the year-to-date period. The long-term earnings growth rate for Dell Technologies is pegged at 26.35%.
Shares of ADI have gained 42.3% in the year-to-date period. The long-term earnings growth rate for Analog Devices is pegged at 28.76%.
Oracle (NYSE: ORCL) is set to pay its quarterly dividend next week, on Friday, July 24, rewarding investors with $0.5 per share.
According to the technology giant’s press release, investors as of July 10 will be eligible for the payment, which remains unchanged from the previous two quarters.
Going by the numbers, 100 ORCL shares will net precisely $50 in quarterly dividends next week.
Oracle dividend calendar. Source: Oracle.com If the payment remains unchanged in the next quarter, investors will receive $200 in annual dividends this year.
However, looking at historical trends, a dividend increase is likely, considering that the company has increased its dividends every year since it began distributing them, with the exception of 2013, when the payout was nearly 43% lower compared to 2012, as per DivvyDiary calendar.
Oracle stock dividend profile Currently, Oracle has a forward dividend yield (FWD) of 1.53%, which is noticeably higher than the sector average of 1.37%. On the other hand, its payout ratio is 18.34, versus the industry 27%.
It also has an annual payout (FWD) of $2, and it pays dividends on a quarterly basis: in January, April, July, and October. The stock has an average price recovery of 7.4 days
While the figures are overall positive, the stock itself has suffered quite a lot this year. For context, an investor who placed $1,000 into Oracle at the beginning of 2026 would have seen the investment generate just about $6.6 in dividends, and they would have recorded a total loss of roughly $335.
In other words, in just over two quarters, the investment would have been worth approximately $665, representing a total loss of 33.5%. On an annualized basis, the investment recorded a compound annual growth rate (CAGR) of -53.66%, highlighting the magnitude of the year-to-date decline.
Featured image via Shutterstock
Best Crypto Exchange for Intermediate Traders and Investors
Invest in cryptocurrencies and 3,000+ other assets including stocks and precious metals.
0% commission on stocks - buy in bulk or just a fraction from as little as $10. Other fees apply. For more information, visit etoro.com/trading/fees.
Copy top-performing traders in real time, automatically.
eToro USA is registered with FINRA for securities trading.
30+ million Users worldwide
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk. Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment and you should not expect to be protected if something goes wrong. Take 2 mins to learn more.
Join Finbold's newsroom, become a Sales Executive today! Apply now to join Finbold as a crypto/finance news writer!
Wells Fargo oznámila za 2. čtvrtletí růst EPS o 25 % na 2 USD a tržeb o 9 %. Banka zároveň potvrdila celoroční výhled čistého úrokového výnosu kolem 50 miliard USD.
Fiserv’s Debit Network Talks Raise a Bigger Question for Visa and MastercardWells Fargo & Company NYSE: WFC reported stronger second-quarter 2026 results, with executives pointing to broad-based revenue growth, disciplined expenses, improved credit performance and balance sheet growth following the removal of the company’s asset cap last year.
Chief Executive Officer Charlie Scharf said diluted earnings per share rose 25% from a year earlier to $2, while revenue increased 9%. Net interest income grew 5%, and non-interest income rose 13%, reflecting what Scharf described as progress toward building a more balanced revenue mix with higher fee-based revenue.
Get Wells Fargo & Company alerts:
3 Big Banks Plan Double Digit Dividend Increases After Passing Fed Stress Test“We are clearly benefiting from the economic strength we see in the U.S., but the investments we are making and our improved operating discipline drove strong momentum and continued to result in improved performance,” Scharf said.
Chief Financial Officer Mike Santomassimo said net income increased 17% year over year to $6.4 billion. The quarter included $132 million, or $0.04 per share, of discrete tax benefits tied to the resolution of prior-period matters.
Revenue Growth Across All Operating Segments Ally Financial Is Back to Basics—And Investors Are WatchingScharf said each of Wells Fargo’s operating segments generated higher net interest income and non-interest income compared with a year earlier. In Consumer Banking and Lending, revenue rose 6%, helped by growth in checking accounts, credit cards and auto lending. Scharf said consumer primary checking accounts have increased year over year for 13 consecutive quarters, supported by investments in marketing and digital account opening.
Credit card momentum continued, with new accounts increasing 46% from a year earlier. Scharf said the company has enhanced its credit card products over the past five years and improved customer experience, but noted that rapid growth in the business carries near-term profitability pressure because of upfront costs tied to marketing, promotional rates, onboarding and reserves. He said card vintages from 2022 through 2024 are now adding to profitability, while larger 2025 and 2026 vintages are still absorbing upfront costs.
Auto lending also expanded, with originations rising 41% year over year and average balances up 31%. Scharf said growth was partly due to Wells Fargo becoming the preferred financing provider for Volkswagen and Audi vehicles in the U.S., adding that credit performance has remained in line with expectations.
In Wealth and Investment Management, revenue increased 13%. Client assets rose 15% to more than $2.4 trillion, driven by higher market valuations and four consecutive quarters of positive net flows. Scharf said Wells Fargo has invested more than $1 billion in recent years to modernize the unit’s technology platform, including the second-quarter launch of Advisor Gateway, a desktop platform with generative AI capabilities.
Investment Banking and Markets Drive CIB Results Corporate and Investment Banking revenue rose 16% from a year earlier. Scharf said markets revenue grew 24%, aided by balance sheet growth to support client financing activity. He noted that while this activity can lower net interest margin because it carries lower spreads, it has “good returns and profitability” and can support broader client relationships.
Santomassimo said Wells Fargo has increased its markets balance sheet by $198 billion since the end of 2024, with about 60% in financing balances, 20% in trading and 20% in lending within the business. He said the company is tracking client-level results and is seeing additional business from clients receiving incremental financing.
Banking revenue within Corporate and Investment Banking rose 20%, supported by investment banking fees and activity in equity and debt capital markets. Santomassimo said firmwide investment banking fees exceeded $900 million in the quarter, a record. Scharf highlighted Wells Fargo’s year-to-date leveraged finance market share of 7.2%, its No. 3 ranking in that category, a 3.8% share in equity capital markets and a move from No. 9 to No. 4 among U.S. advisors by announced M&A deal volume.
Commercial Banking revenue increased 6% from a year earlier. Scharf said targeted hiring in 20 high-density markets where Wells Fargo is under-penetrated has helped drive client growth and higher loan and deposit balances. He also said the company is investing in treasury management and payments, including blockchain-based payment rails intended to make cross-border payments faster, more transparent and more predictable.
Expenses, Headcount and Capital Returns Expenses increased 2% from a year earlier, reflecting investments in technology, advertising and revenue-related compensation, partially offset by efficiency initiatives. Santomassimo said Wells Fargo’s efficiency ratio improved to 60%, down four percentage points from a year earlier.
Scharf said headcount has declined for 24 consecutive quarters. The company ended the second quarter with 197,000 employees, down 79,000 from six years ago, 15,000 from last year and 3,500 from the prior quarter. He said Wells Fargo is using those efficiencies to fund investments including branch bankers, investment advisors, commercial banking relationship managers, investment bankers, traders, marketing, product development, AI and cybersecurity.
Wells Fargo returned more than $9.8 billion of capital to shareholders in the first half of 2026, including $7 billion of common stock repurchases. Santomassimo said the company repurchased $3 billion of common stock in the second quarter, and common shares outstanding declined 6% from a year earlier. The company’s common equity Tier 1 ratio was 10.3%, within its 10% to 10.5% target range and above its regulatory minimum plus buffers of 8.5%.
Scharf said Wells Fargo expects to raise its third-quarter common stock dividend by 11% to $0.50 per share, subject to board approval later this month.
Credit Quality Remains Strong Executives said credit performance remained strong across consumer and commercial portfolios. Santomassimo said the net loan charge-off ratio declined 10 basis points from a year earlier to 34 basis points of average loans. Commercial net loan charge-offs declined to 10 basis points, while consumer loan charge-offs also improved, including continued net recoveries in residential mortgage.
During the question-and-answer session, Santomassimo said consumer delinquency trends have been better than the company modeled throughout the year, with no meaningful deterioration by FICO score or income cohort. He also said Wells Fargo is not seeing systemic issues in the commercial portfolio, though individual borrower issues can arise.
Asked about underwriting conditions, Scharf said consumer lending competition appears broadly consistent, but he described wholesale lending as more varied. He said significant capital is being deployed by banks and non-banks across risk assets, including areas related to data centers and strategic transactions. Scharf said Wells Fargo is staying within its risk tolerances and underwriting only the parts of transactions where it is comfortable with the credit profile.
Outlook Maintained as NIM Remains in Focus Santomassimo said Wells Fargo is maintaining its full-year 2026 net interest income outlook of approximately $50 billion, including about $48 billion excluding markets and about $2 billion from markets. He said average loans rose 12% year over year in the second quarter, and loan growth in the fourth quarter is likely to exceed the mid-single-digit increase the company assumed in January.
Net interest margin declined four basis points from the first quarter, which Santomassimo attributed mainly to growth in interest-bearing deposits and continued growth in markets activity. He said Wells Fargo expects modest net interest margin compression in the third quarter, broadly in line with the second-quarter decline, before stabilization in the fourth quarter.
In response to analyst questions, Scharf emphasized that the pressure on net interest margin is tied to deliberate growth decisions, particularly in markets financing and interest-bearing deposit growth, rather than factors simply “happening” to the company. He said Wells Fargo can slow or reverse some activity if it does not generate the expected returns, but added that early results show higher trading revenue and share gains from clients receiving financing.
Wells Fargo also maintained its 2026 non-interest expense outlook of approximately $55.7 billion. Santomassimo said first-half expenses were in line with expectations, and higher revenue-related expenses in the second half are expected to be offset by efficiency initiatives elsewhere.
Scharf reiterated confidence in Wells Fargo’s medium-term target of a sustainable return on tangible common equity of 17% to 18%. The company reported ROTCE of 17.7% in the second quarter and 16.1% for the first half of 2026. Scharf said venture capital equity gains helped returns in the quarter, but he said broader growth and efficiency trends are what support confidence in reaching the target over a “reasonable timeframe,” assuming favorable conditions continue.
About Wells Fargo & Company NYSE: WFCWells Fargo & Company is a diversified, U.S.-based financial services company headquartered in San Francisco, California. Founded in 1852 by Henry Wells and William G. Fargo, the firm has evolved from its origins in express delivery and pioneer-era banking into one of the largest full-service banks in the United States. The company provides a broad range of financial products and services to individual, small business, commercial, and institutional clients. Charles W. Scharf serves as chief executive officer.
Wells Fargo operates across several core business segments, including consumer banking and lending, commercial banking, corporate and investment banking, and wealth and investment management.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Should You Invest $1,000 in Wells Fargo & Company Right Now?Before you consider Wells Fargo & Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Wells Fargo & Company wasn't on the list.
While Wells Fargo & Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Nobody hacked anything. No smart contract failed, no private key leaked, no phishing link fired. On July 6, the treasury of BonkDAO, the community organization behind one of Solana’s flagship memecoins, transferred roughly $20 million worth of BONK to a wallet controlled by an attacker, and every step of the transfer was a valid transaction executed exactly as the DAO’s own rules prescribed.
Summary
An attacker spent about $4.4 million to gain enough BONK voting power and passed a proposal that transferred nearly $20 million from the BonkDAO treasury. The incident exposed how low voter participation, no timelock, and automatic proposal execution left the DAO vulnerable to governance capture. The treasury drain has renewed calls for stronger DAO safeguards as exchanges, investigators, and the broader crypto industry assess the aftermath. The attacker did not break the governance system. They bought it, for about $4.4 million, at an implied return of nearly five to one, in a vote where seven wallets participated and more than 18,000 members did not. The episode is the cleanest proof to date of an uncomfortable truth the industry has spent years politely ignoring: a treasury governed by token-weighted voting is worth exactly the cost of assembling a temporary majority, and for most DAOs, that cost is a fraction of the prize.
The mechanics deserve a careful walkthrough because the details are what turn a crime story into a design lesson. And the aftermath, exchanges freezing deposits, law enforcement notified, a philosophical fight over whether this was theft at all, will shape how every treasury-holding DAO on every chain rewrites its rules over the next year.
Six days in the open The attack was not fast, and it was not hidden. On June 30, an anonymous wallet submitted a proposal to BonkDAO’s governance system, which runs on Realms, Solana’s standard DAO tooling. The proposal carried the title BIP #76, styled itself as a governance renewal plan, and dressed the theft in the language of turnaround management: install new leadership, restructure the council, monetize treasury holdings, stop the bleeding. It even included a line noting that yes-voters would be eligible to receive tokens, a detail that reads in hindsight like a dark joke about incentive design. Beneath the rhetoric sat the only clause that mattered: an instruction to transfer 4.43 trillion BONK, the bulk of the treasury, to a wallet the proposer controlled.
The proposal stayed live for six days. During that window, the attacker methodically accumulated voting power, spending approximately $4.4 million buying BONK through exchange wallets, an amount equal to just over 1% of total supply but decisive against the DAO’s quorum arithmetic. On-chain researchers, including Yu Xian of security firm SlowMist and the analyst Yu Jin, later reconstructed the accumulation pattern: purchases sized to clear the quorum threshold with minimal excess, executed while the proposal sat in plain sight and no meaningful opposition organized. On July 6, the attacker cast the assembled stake. The final tally showed 882.38 billion BONK in favor against a quorum threshold of 879.95 billion, a margin so narrow it amounts to the attacker buying the exact number of votes required and almost nothing more.
Turnout was 2.9%. The yes share was 99.9%, which is what unanimity looks like when a single voter agrees with itself.
Then the system worked as designed, which is the entire problem. Realms-based governance executes passed proposals automatically. No human signed off, no council reviewed the transfer, no delay separated approval from execution. The treasury moved to an address ending in JHvQ, which investigators traced to funding from a Bybit account, and portions began flowing toward exchanges within hours.
The anatomy of the failure Three missing safeguards converted a bad proposal into an executed one, and each is a standard control the DAO simply did not have. The first is a timelock: a mandatory delay between a proposal passing and its instructions executing. Even a 48-hour window would have given the community, or the core team, time to see a treasury-draining transfer queued and organize a response. The second is a multisig or council veto: an emergency brake allowing designated signers to freeze anomalous executions. The third is quorum and participation design: a system where 1% of supply can constitute a passing majority against 2.9% turnout has set its security budget equal to the apathy of its members.
The deeper failure sits above all three: the treasury’s size bore no relationship to the cost of controlling it. BonkDAO held roughly 15% of all circulating BONK, a war chest accumulated through the token’s boom years, governed by a mechanism whose capture cost floated with the token’s price and its holders’ attention. The attacker’s arithmetic was public information. Anyone could compute that quorum, multiplied by market price, cost about $4 million to satisfy, against a treasury worth five times that. The only surprising thing about the attack is that it took until 2026.
The pattern has a canonical ancestor. In 2022, an attacker used a flash loan to seize voting control of Beanstalk, a DeFi protocol, and drained about $180 million in the same block. The industry’s response then was to treat flash-loan governance as the flaw: protocols added voting delays that made borrowed tokens useless for instant capture. BonkDAO’s attacker needed no flash loan. They used patient capital, real purchases held across days, which defeats the flash-loan defenses entirely and shows that the vulnerability was never the loan. It was the market for votes itself.
The market for votes was always there The uncomfortable context is that vote buying in DAO governance is not a fringe exploit; it is an industry with infrastructure. Bribe markets, where protocols openly pay token holders to vote for emissions and incentives, have operated for years around the largest DeFi governance systems and are treated as legitimate yield. Vote-lending and delegation markets let holders rent their governance power without selling their tokens. The line between that accepted economy and what happened to BonkDAO is intent, not mechanism: the machinery for converting money into votes was built, normalized, and liquid long before someone aimed it at a treasury instead of an emissions gauge.
That normalization is why the security framing has to be economic instead of technical. Auditors evaluate smart contracts against code exploits and can certify a system bug-free while it remains trivially capturable, because capture is not a bug. The relevant metric, which security researchers have urged for years under the name cost of corruption, compares the expense of acquiring decisive voting power against the value extractable by wielding it. For a healthy system, the first number exceeds the second with a wide margin. BonkDAO’s ratio, roughly $4.4 million against $20 million, was not marginal. It was an arbitrage with a six-day settlement period, advertised on a public governance forum. Any DAO that has never computed its own ratio should assume an attacker has.
The turnout side of the ratio deserves equal weight, because the attacker’s capital did not defeat 18,000 members; it defeated their absence. Governance participation across the industry has decayed for years, from the double-digit turnout of early experiments to the low single digits typical today, as token holders rationally conclude that reading proposals is unpaid labor with diluted influence. Every percentage point of apathy directly lowers the capture price. In that sense, the $4.4 million was not the cost of beating BonkDAO’s community. It was the market-clearing price of its indifference, and comparable prices are computable for hundreds of treasuries right now.
The tooling default problem A quieter thread of the postmortem concerns Realms, the standard governance stack on Solana, and by extension the defaults every DAO platform ships. Nothing in the incident involved a flaw in the tooling: Realms executed a validly passed proposal, which is its job. But defaults are policy, and the configuration this DAO ran, automatic execution, no timelock, a static quorum set long ago, is the path of least resistance the tooling made easy. The same critique applies across ecosystems, where governance frameworks expose timelocks and councils as optional modules that busy launch teams skip. The predictable industry response is already forming: platforms moving protective defaults from opt-in to opt-out, warning surfaces that flag treasury-moving instructions in plain language, and simulation tools that show voters exactly what a proposal executes before they approve it. None of that required new research. It required a $20 million proof that someone would actually pull the trigger.
Theft, or the rules working The philosophical fight broke out immediately and is more consequential than it sounds. One camp, including a notable contingent of on-chain observers, argues that nothing was stolen: the attacker followed every rule, won a vote the rules recognized, and executed a transfer the rules authorized. Code was law, the law was bad, and the losses are tuition. The proposal was public for six days; 18,000 members who could not be bothered to vote against their own treasury made a governance decision by omission. On this reading, the term “attack” launders negligence into victimhood, and law enforcement involvement sets a precedent that undermines the entire premise of on-chain governance: if valid votes can be criminal, then governance outcomes are subject to off-chain veto, and the system’s guarantees mean nothing.
The opposing camp, which includes BonkDAO itself, the analytics firms tracking the funds, and figures like Ripple’s chief technology officer emeritus David Schwartz, who compared the maneuver to corporate fraud, argues that legality is not defined by protocol validity. A proposal that misrepresents its purpose, transfers assets to its author, and relies on engineered low turnout is fraud in any legal system humans have built, regardless of how faithfully the machinery executed it. Corporate law developed exactly these doctrines for exactly these reasons: shareholder votes procured through deception are voidable, and control acquired to loot a treasury is a breach the courts unwind. The wrapper being a DAO does not repeal centuries of fiduciary reasoning.
The debate matters practically because it decides where defense happens. If this is theft, then exchanges freezing funds, as Upbit did when it suspended BONK deposits and withdrawals, and law enforcement tracing the Bybit-funded wallet are the immune system working. If this is the rules working, then every defense must live on-chain, in timelocks and vetoes and quorum design, and off-chain recovery is itself the attack on the system. The industry visibly believes both things at once, which is why the response has been both a law enforcement referral and a wave of emergency governance reviews at other DAOs.
What BONK was, and what the treasury was for The scale of the loss only registers against what the DAO had built. BONK launched in December 2022 as Solana’s answer to its darkest hour, airdropping half its supply to the ecosystem’s users, developers, and artists in the weeks after the FTX collapse had cratered confidence in the chain. The distribution strategy worked beyond any reasonable expectation: the token became the community flag of Solana’s recovery, integrated across hundreds of applications, listed on every major venue, and eventually the anchor of an ecosystem spanning launchpads, exchanges, and grant programs. The treasury at the center of this month’s attack was the accumulated war chest of that run, holding roughly 15% of supply and funding the buybacks, integrations, and community programs that separated BONK from the thousands of memecoins that mint, spike, and vanish.
That history is why the governance failure stings beyond the dollar figure. The DAO structure was not decoration; it was the mechanism by which a token with no product and no cash flows coordinated thousands of contributors for three years. The treasury was the proof that memecoin communities could accumulate and steward real resources. Its draining through a seven-wallet vote is therefore an attack on the category’s best argument for itself, and every project that pitched community treasuries as the moat now answers for the moat’s price tag.
The damage, priced The market’s verdict was swift but contained. BONK fell between 8 and 10% on the disclosure, trading around levels that left its market capitalization near $400 million, and stabilized within days. Several factors capped the damage. The stolen tokens, more than 4.4 trillion BONK, represent supply that was already outside the market in a treasury, so the theft’s mechanical effect is a transfer of overhang rather than new emission, though overhang in hostile hands is worth less than overhang in friendly ones. Exchange coordination raised the realistic prospect of partial recovery or at least slowed liquidation. And the token’s price had already absorbed a brutal year alongside the whole memecoin complex, whose aggregate value sits more than 50% below its level of twelve months ago even after a July bounce, leaving less speculative premium to destroy.
No user wallets were touched, and the BONK token contract itself was never at issue, distinctions that matter for the asset’s survival. The loss is concentrated in the commons: the treasury that funded ecosystem grants, marketing, and the buyback programs that gave the DAO its purpose. For a memecoin, whose entire value proposition is community coordination, draining the coordination budget through the coordination mechanism is a uniquely poetic wound, as crypto.news noted in its report on the treasury raid. The token survives; the question is whether the institution does.
The recovery race Recovery, if it happens, will happen at the choke points, and the first week showed both their power and their limits. Stolen tokens moving toward centralized exchanges triggered the standard playbook: BonkDAO identified the exchange wallets used to accumulate BONK before the vote, notified law enforcement, and coordinated with exchanges, bridges, and the Solana Foundation. Upbit’s suspension of BONK deposits and withdrawals closed one of the deepest liquidity venues to the attacker, and the wallet trail through a Bybit-funded account gives investigators a potential identity thread, since major exchanges hold verified customer records behind funded accounts.
The limits are equally real. On-chain funds that stay on-chain remain beyond freezing, and an attacker with $20 million of patience can wait out attention, launder through decentralized venues, or drip supply into liquidity over months. Security analysts examining the movement patterns flagged infrastructure choices that complicate tracing, and the history of comparable incidents suggests recoveries are partial when they happen at all, often arriving through negotiated returns, the white-hat conversion, where an attacker keeps a bounty-sized fraction, more often than through seizure. The realistic best case is not restoration but attrition: enough friction at every exit that liquidation becomes slow, discounted, and legally dangerous, which changes the attacker’s arithmetic retroactively and, more importantly, changes it prospectively for the next one running the same computation against another treasury.
The regulatory shadow The episode also lands in the middle of a live legislative fight, and lawmakers hostile to DeFi could not have commissioned a better exhibit. The CLARITY Act’s most contested sections concern exactly this territory: what obligations attach to decentralized systems, who bears responsibility when autonomous code moves other people’s money, and whether governance token holders or developers stand behind the structures they launch. A $20 million treasury vanishing through a valid vote, followed by an appeal to the very law enforcement the system was designed to route around, hands skeptics their argument in a single anecdote: the industry wants code to be law until code loses, at which point it wants law to be law. Advocates will answer that the failure was one badly configured DAO, not the model, and that the response, exchanges, analytics firms, and police cooperating within hours, shows the accountability layer functioning. Both arguments will be quoted in committee, and the regulation debate will price the incident long after the market has forgotten it.
There is a subtler legal exposure inside the DAO structure itself. If courts or regulators conclude that governance token voting constitutes control, then large holders who do vote may carry duties toward the treasury they direct, an outcome that would make participation more dangerous than apathy and invert the incentive problem the industry is trying to fix. The unresolved status of DAO legal personhood, patched in a few jurisdictions through wrapper statutes and ignored in most, means every treasury of size is now a test case waiting for its plaintiff.
What every other DAO does now The practical legacy of BIP #76 is a checklist already circulating through governance forums across Solana and every other ecosystem. Timelocks on treasury-affecting proposals move from best practice to table stakes, with delays scaled to transfer size. Emergency veto councils, unfashionable for years because they reintroduce trusted parties into trustless systems, return to favor with sunset clauses and narrow mandates as the compromise. Quorum design gets rethought around adversarial math: thresholds set as a function of treasury value and float cost, not as static%ages chosen at launch when nobody imagined the treasury would be worth stealing. Proposal screening adds friction, deposit requirements, and mandatory review windows for any instruction that moves funds. And delegation programs attempt to fix the underlying disease, the 2.9% turnout, by concentrating voting power in accountable delegates who show up.
Each fix carries its own cost, and the honest version of the checklist admits it. Timelocks slow legitimate operations and give markets time to front-run treasury actions. Vetoes recreate the trusted committee that DAOs were invented to remove, and committees can be captured too, or become liability magnets under exactly the legal theories the theft camp invoked. High quorums can freeze governance entirely in low-attention projects, converting treasuries into unspendable monuments. The design space has no free choices, only tradeoffs between capture resistance and operational capacity, and every DAO is now pricing those tradeoffs under deadline.
The DeFi sector’s broader security picture sharpens the urgency. The same week brought a $9 million oracle exploit on a Hedera lending protocol and an active drain at a yield platform flagged mid-attack by security monitors, part of a first half that set records for incident count. Governance capture now joins oracle manipulation and bridge compromise on the standing threat list, with one distinction that makes it worse: it scales with legitimacy. The more valuable and decentralized a DAO becomes, the more its governance token trades freely, and the more liquid the market for its own capture.
The watchlist for holders and builders For anyone holding BONK or tokens governed by similar structures, the incident reduces to observable signals. On the recovery track: movement from the JHvQ-linked wallets, exchange announcements about frozen or returned funds, and any communication suggesting a negotiated settlement, each of which reprices both the treasury and the overhang. On the reform track: the text of the DAO’s emergency proposals, whether they include timelocks and a veto council, and crucially the turnout they attract, since a reform vote that passes with the same 2.9% participation has fixed the paperwork and not the disease. On the contagion track: whether other large-treasury DAOs disclose their own capture math and patch it publicly, or wait for their own BIP #76.
Builders face a starker version of the same list. Compute the cost of corruption for your own system today: quorum threshold times token price against extractable treasury value, adjusted for realistic turnout. If the ratio is unfavorable, every day it stays public is a day the trade is live for someone else. The defenses are neither novel nor expensive, which is exactly why their absence will stop being forgivable. Before July 6, an unprotected treasury was a theoretical risk that governance forums debated in the abstract. After it, the exploit is documented, the playbook is public, the return profile is proven, and the next attacker does not need to innovate. They need to search.
There is also a quieter question for the Solana ecosystem specifically, which had, by most measures, its strongest institutional month on record even as the attack unfolded: whether the maturity narrative absorbs the incident or gets dented by it. The honest answer is that the two stories are about different layers. The chain performed flawlessly throughout; the failure lived entirely in one organization’s configuration of one governance application. Institutions doing diligence understand that distinction. Retail sentiment, which still drives the memecoin complex that BONK anchors, often does not, and the gap between those two readings will be visible in the relative performance of governance-token projects for quarters.
The bill for cheap governance comes due For BONK itself, the path from here runs through three questions. Whether exchange and law enforcement coordination claws back a meaningful share of the 4.4 trillion tokens, where each recovered tranche is both treasury restoration and supply certainty. Whether the DAO can pass its own emergency reforms through the very mechanism that just failed, a live experiment in whether a captured system can vote itself better armor. And whether the community that made BONK one of the defining tokens of the meme coin era treats the episode as a death knell or a founding trauma; communities have rallied around less. The token has survived worse markets than this news.
For everyone else, the lesson costs nothing and is therefore priceless. Every DAO treasury on every chain now has a public quote for what its governance is worth: the market price of its quorum. If that number is smaller than the treasury, the treasury is not owned, it is rented, and the rent is whatever an attacker pays for the votes.
BonkDAO’s members learned the rent on a Monday in July. The rest of the industry gets to learn it from the outside, which is the only cheap way the lesson is ever taught.
Disclaimer: This article is information, not investment advice. Figures, on-chain attributions, and recovery prospects reflect reporting available as of July 14, 2026, and can change as investigations proceed. Characterizations of the incident as theft or as valid governance are contested. Nothing here is a recommendation to buy or sell BONK or any other asset. Verify current developments from primary sources and consider your own circumstances before making any decision.
ConfirmoPay spustil Subscribe pro automatické opakované platby v USDC na Solaně. Služba cílí na SaaS firmy a využívá předautorizované on-chain převody.
If you’ve ever dealt with failed credit card charges on a SaaS subscription, you know the pain. ConfirmoPay thinks stablecoins can fix that, and it just shipped a product to prove it.
The crypto payment gateway has launched Subscribe, a service that lets businesses automate recurring USDC collections on Solana. Think of it as Stripe’s subscription billing, except the rails are a blockchain instead of Visa’s network. No third-party processors, no manual invoicing, just programmatic money movement.
How Subscribe actually works Subscribe builds on Solana’s Subscriptions & Allowances program, which launched on June 2, 2026. That program essentially lets users pre-authorize recurring token transfers from their wallets, similar to how you’d set up autopay with a bank account, except entirely on-chain.
In English: a customer approves a spending allowance for a merchant, and the merchant can automatically pull the agreed-upon USDC amount at regular intervals. No card networks skimming fees. No chargebacks. No “your payment method has expired” emails.
Advertisement
The service supports SPL tokens and Token-2022, including confidential transfers. That last bit matters because it means businesses can process payments with an added privacy layer, something enterprise clients tend to care about quite a lot when moving money around.
ConfirmoPay is targeting SaaS businesses specifically, which makes sense. Subscription software companies live and die by recurring revenue, and any friction in the billing process directly hits their bottom line. Traditional payment processors typically take 2.9% plus a per-transaction fee on recurring charges. On-chain settlement on Solana costs a fraction of a cent.
The company behind the product ConfirmoPay isn’t some weekend hackathon project. The company, operating under the Confirmo brand, has been in the crypto payments space for over 12 years. That’s practically ancient by industry standards, predating most of the tokens people trade today.
The numbers back up the track record. Confirmo processes more than $80 million monthly for enterprise clients across 141 countries. The platform runs at 99.97% uptime, which translates to roughly 2.6 hours of downtime per year.
Subscribe joins an existing product suite that already includes Checkout, Deposits, and Payouts. The company is also licensed under the EU’s MiCA regulations, giving it a compliance foundation that many crypto payment startups still lack.
Why Solana, and why now Solana has been methodically building out its payment infrastructure for years. The chain launched Solana Pay back in 2022, establishing its ambitions in the commerce space early. Since then, the ecosystem has expanded through integrations with firms like Helius, Dynamic, and Mesh, all of which served as design partners for the Subscriptions & Allowances program.
What this means for investors Processing $80 million monthly already puts Confirmo in serious territory. For comparison, that’s nearly a billion dollars annually flowing through a single crypto payment processor.
The risk side of the equation isn’t trivial either. Stablecoin regulatory frameworks are still evolving globally, and any changes to USDC’s status or Solana’s regulatory treatment could impact the viability of products built on top of them.
For those tracking the Solana ecosystem specifically, the Subscriptions & Allowances program represents a meaningful infrastructure upgrade that goes beyond ConfirmoPay. The design partners already involved, including Helius, Dynamic, and Mesh, suggest this is being treated as core infrastructure rather than a peripheral feature.
Disclosure: This article was edited by Editorial Team. For more information on how we create and review content, see our Editorial Policy.
Palantir v 1. čtvrtletí 2026 zvýšil tržby o 85 %, v USA v komerční části o 133 %, a dosáhl 60% upravené provozní marže. Firma tak spojuje rychlý růst se ziskovostí.
Key Takeaways PLTR's Ontology organizes enterprise data into an operational framework that becomes more valuable over time.Palantir delivered 85% revenue growth, 133% U.S. commercial growth and a 60% adjusted operating margin.PLTR combines rapid growth and profitability, distinguishing it from AI software peers. Palantir (PLTR - Free Report) is increasingly distinguishing itself through an advantage that extends well beyond artificial intelligence models. At the heart of its platform is the Ontology, which organizes enterprise data into a connected operational framework that customers can continuously build upon.
Years of deployments across hundreds of organizations have created deeply integrated systems that are difficult and time-consuming to replace. This accumulated implementation expertise, strengthened by Palantir’s forward-deployed engineering model and long-standing government security credentials, makes the platform more valuable with every deployment.
Unlike AI developers that primarily compete on models, Palantir monetizes the operational layer where AI is applied, allowing its software to retain value even as foundation models become increasingly commoditized.
Palantir vs. AI Software PeersPLTR’s competitive strengths are reflected in its financial performance. The company delivered 85% revenue growth in the first quarter of 2026, including an exceptional 133% increase in U.S. commercial revenues, while generating a 60% adjusted operating margin and a 53% GAAP net margin. Even leading AI software companies like Datadog (DDOG - Free Report) and Snowflake (SNOW - Free Report) struggle to match this combination of rapid expansion and profitability.
While DDOG and SNOW continue to benefit from AI demand, their growth rates remain significantly lower. By combining a durable software foundation with industry-specific expertise and superior execution, Palantir continues to separate itself from DDOG, SNOW and traditional enterprise software competitors.
PLTR’s Price Performance & EstimatesThe stock has declined 27% year to date compared with the industry’s 5% fall.
Image Source: Zacks Investment Research
From a valuation standpoint, PLTR trades at a forward price-to-sales ratio of 33.13X, well above the industry’s 4.08X. It carries a Value Score of F.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for PLTR’s 2026 earnings declined over the past 60 days.
Image Source: Zacks Investment Research
PLTR currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Pfizer v onkologii těží z akvizice Seagen, když výnosy této divize vzrostly o 9 % na 3,83 miliardy USD. Amgenu naopak škodí pokles starších léků, zejména Prolia a Enbrel.
Pfizer (NYSE: PFE | PFE Price Prediction) and Amgen (NASDAQ: AMGN) both reported Q1 2026 results this quarter, and the numbers reveal two very different bets on the future of oncology. Pfizer is monetizing its Seagen deal today. Amgen is defending a biosimilar cliff while spending to rebuild growth from scratch.
Padcev Carries Pfizer. Biosimilars Bite Amgen. Pfizer’s oncology franchise pulled in $3.83 billion, up 9% year over year, led by Seagen’s crown jewel Padcev at $591 million (+39%) on first-line urothelial share gains. Lorbrena jumped 37%, Orgovyx 43%, and total launched and acquired products grew 22% operationally. That is real commercial momentum.
Amgen’s story is bifurcated. IMDELLTRA soared 219% to $258 million and UPLIZNA jumped 188%, yet legacy supportive care crumbled. Prolia fell 34% to $727 million, XGEVA dropped 27%, and Enbrel slid 37% under Medicare Part D price setting. CEO Robert Bradway framed it optimistically, noting “16 brands achieving double-digit growth, enabling us to grow through expected patent expirations”. The math is tighter than the tone suggests.
Business Driver Pfizer Amgen Oncology engine Seagen ADCs (Padcev, Tukysa) BiTE platform (IMDELLTRA) Biggest drag COVID: Comirnaty -59% Prolia biosimilars -34% Revenue growth +5.4% +5.76% Monetizing Assets vs. Rebuilding a Base Albert Bourla said Pfizer is “off to a strong start in 2026” and singled out oncology and obesity as areas where he expects Pfizer to lead. That confidence rests on existing revenue streams already booking growth. Padcev’s Phase 3 EV-304 trial showed a 47% reduction in tumor recurrence, progression or death in MIBC patients, with a PDUFA target of August 17, 2026.
Amgen’s counter is capital-intensive. MariTide obesity trials, Xaluritamig in prostate cancer, and biosimilars for KEYTRUDA and OPDIVO all require years of spend before payback. Debt sits at $57.3 billion. Amgen is pivoting heavy capital into high-risk, early-stage platforms just to defend its baseline.
The Padcev PDUFA and MariTide Readouts Will Set the Tone I will be watching Padcev’s August 17 PDUFA decision, Elrexfio’s myeloma expansion, and whether Pfizer can hold its reaffirmed $59.5 to $62.5 billion revenue guide against a $1.5 billion generic headwind. For Amgen, MariTide Phase 3 readouts and the pace of Prolia erosion matter most. Any acceleration there pressures the $37.1 to $38.5 billion full-year guide.
Why I Lean Toward Pfizer for Oncology Alpha Personally, I lean Pfizer here. You are paying a forward P/E of 8 for a business collecting cash today from Seagen assets, versus 17 for Amgen’s rebuild story. The 7.07% dividend yield compensates holders during the wait. Amgen’s stock has run 14.1% YTD while Pfizer is flat at -0.07%, which is exactly why I find PFE more interesting now. Investors focused on the growth narrative who can tolerate biosimilar drag will find Amgen’s setup more compelling. If input costs stay volatile and MFN pricing tightens, the cheaper multiple and the working oncology franchise become more attractive on a relative basis.
Meet America's Newest $1b Unicorn (Sponsor) A US startup just passed a $1 billion private valuation, joining billion-dollar private companies like OpenAI and ByteDance. Unlike those other unicorns, you can invest in EnergyX right now; but only until July 16.
Over 50,000 people already have, along with global giants like General Motors and POSCO.
Here's why there's so much interest: EnergyX's patented tech can recover up to 3X more lithium than traditional methods. That's a big deal, as demand for lithium is expected to 5X current production levels by 2040. Become an early-stage EnergyX shareholder before the 7/16 investment deadline.
MercadoLibre v 1. čtvrtletí 2026 zvýšila cross-border GMV o 68 % meziročně na bázi očištěné o vliv kurzů. Růst táhly free shipping, multi-seller košíky a silnější nabídka z Číny.
Key Takeaways MercadoLibre's cross-border GMV rose 68% year over year on an FX-neutral basis in Q1 2026.Free shipping, multi-seller carts, seller incentives and a China fulfillment center reduced friction.Argentina and Andean markets are adding growth as broader assortment supports the model's scale. MercadoLibre, Inc. (MELI - Free Report) is aggressively scaling its cross-border trade as a potential long-term growth driver. The company recorded impressive 68% year-over-year, foreign-exchange-neutral gross merchandise volume growth for the segment in the first quarter of 2026. This momentum indicates that international commerce is becoming a crucial operational layer alongside the core local marketplace.
The company believes it holds a unique position by connecting merchants in China and the United States with buyers across Latin America. Chinese suppliers, in particular, offer competitive prices, rapid product innovation and broad merchandise selection, helping MercadoLibre address growing consumer demand for affordability and assortment.
The business underwent meaningful changes during 2025. MercadoLibre simplified access to free shipping, introduced multi-seller shopping carts, expanded seller incentives and increased its presence in China, including opening its first fulfillment center there. These initiatives were designed to remove friction from the international drop-shipping model while improving execution and merchant relationships.
Growth is no longer concentrated in Mexico alone. Argentina and the Andean countries are contributing more meaningfully to cross-border trade growth, while markets such as Colombia and Peru benefit from broader product assortment where local seller networks are less developed.
MercadoLibre believes this model can become profitable as scale improves. By expanding product availability, improving delivery capabilities and strengthening merchant participation, cross-border trade is evolving into an increasingly important component of the company's marketplace strategy rather than simply an incremental international offering.
What the Latest Metrics Say About MercadoLibreMercadoLibre, which competes with Amazon.com, Inc. (AMZN - Free Report) and Sea Limited (SE - Free Report) , has seen its shares tumble 11.1% over the past six months compared with the industry’s 3.4% decline. While shares of Amazon have jumped 3.8%, those of Sea Limited have fallen 10.8% in the aforementioned period.
Image Source: Zacks Investment Research
From a valuation standpoint, MercadoLibre's forward 12-month price-to-earnings (P/E) ratio stands at 36.43, higher than the industry’s ratio of 21.94. The stock is also trading above its 12-month median level of 34.46.
MercadoLibre is trading at a premium to Amazon (with a forward 12-month P/E ratio of 25.97) and Sea Limited (22.29).
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for MercadoLibre’s current financial-year sales and earnings per share implies year-over-year growth of 39.7% and 4%, respectively. For the next fiscal year, the consensus estimate indicates a 26.6% rise in sales and 47% growth in earnings.
Image Source: Zacks Investment Research
MELI currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Abbott oznámí výsledky za 2. čtvrtletí 2026 16. července; trh očekává EPS 1,28 USD a tržby 12,48 mld. USD. Akcie za poslední tři měsíce klesly o 11,4 %.
Key Takeaways Abbott is expected to report Q2 EPS of $1.28 on $12.48B in revenues, up 1.6% and 12% year over year.ABT may benefit from Core Lab, Cancer Diagnostics, cardiovascular devices and EPD, while Nutrition stays weak.ABT trades below its historical valuation despite recent share weakness ahead of its July 16 earnings report. Abbott Laboratories (ABT - Free Report) is slated to report its second-quarter 2026 results on July 16, before the opening bell.
The Zacks Consensus Estimate for the company’s second-quarter earnings per share (EPS) suggests 1.6% year-over-year growth to $1.28. The estimate has remained constant in the past 60 days. The consensus mark for second-quarter revenues currently stands at $12.48 billion, implying a 12% increase over the prior-year period.
Image Source: Zacks Investment Research
In the trailing four quarters, the company topped earnings estimates twice and broke even on two occasions, the average surprise being 0.42%.
Image Source: Zacks Investment Research
Q2 Earnings Whispers for AbbottPer our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, has a higher chance of beating estimates. This is not the case here, as you can see below.
Earnings ESP: Abbott has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
Zacks Rank:The company currently carries a Zacks Rank #3. You can see the complete list of today’s Zacks Rank #1 stocks here.
Factors Likely to Have Shaped ABT’s Q2 PerformanceDiagnosticsWithin this segment, Abbott may have delivered mixed performance in the second quarter. Rapid and Molecular Diagnostics are likely to have continued to face reduced demand for respiratory virus testing. At the same time, steady demand for the Core Lab diagnostic tests may have been a tailwind, with strong performance across the United States, Europe and Latin America.
Following the acquisition of Exact Sciences, Abbott added the Cancer Diagnostics business, expanding into one of the fastest-growing areas of healthcare. We assume the division to have favorably impacted the quarter’s results, driven by the Cologuard colorectal cancer (CRC) test momentum and contributions from the international markets.
A positive development in the quarter was the American Cancer Society’s updated CRC screening guidelines, reaffirming Cologuard and Cologuard Plus as preferred non-invasive screening options for adults aged 45 and older who are at average risk. This is expected to have positively boosted adoption trends and revenues.
The Zacks Consensus Estimate anticipates Diagnostics revenues to increase 41.6% year over year.
Established Pharmaceutical Products (“EPD”)The segment is expected to have maintained its growth momentum in key emerging markets, supported by favorable long-term health care, economic and demographic trends, with a broad product offering across five therapeutic areas. The biosimilars portfolio, which has expanded to include several market-leading oncology therapies, may have been a positive driver as well for the segment’s top line.
Going by the Zacks Consensus Estimate, EPD revenues are likely to grow 6.6% from the prior-period levels.
Medical DevicesAbbott’s cardiovascular businesses are expected to have been the biggest contributor to Medical Devices’ top line in the second quarter of 2026.
Electrophysiology performance may have been boosted by contributions from the Volt and TactiFlex Duo pulsed field ablation (PFA) catheters. Rhythm Management likely continued to outpace the market, driven by the Aveir leadless pacemaker. Heart Failure business results may have benefited from the Heart Assist Devices portfolio.
In Vascular, the company secured FDA clearance and CE Mark for its next-generation Ultreon 3.0 Software in the quarter, bringing coronary imaging and AI-automated insights together in one system. The enhanced coronary portfolio likely contributed positively to the quarter’s results.
In Neuromodulation, Abbott’s rechargeable spinal cord stimulation device Eterna may have continued to see strong international adoption trends.
Further, the Diabetes Care business may have regained growth momentum following the easing of temporary headwinds, including a delay in the international tender renewal process and a challenging prior-period comparison.
The Zacks Consensus Estimate expects Medical Devices revenues to increase 8.5% year over year.
NutritionThe segment is expected to have faced revenue pressure in the second quarter, as Abbott continues to transition toward a more sustainable balance between price and volume-driven growth. Sales volumes across both pediatric and adult nutritional product portfolios in the United States and internationally may have been lower. Although management reported early progress from these strategic actions in the previous quarter, it is yet to fully materialize.
The Zacks Consensus Estimate indicates Nutrition revenues will decline 4.3% year over year.
Abbott’s Peers Reporting Next WeekQuest Diagnostics (DGX - Free Report) is set to report second-quarter 2026 results on July 23, before the opening bell. The company’s Diagnostic Information Services segment is expected to have maintained its growth momentum, supported by organic growth across the physician, hospital and consumer channels. Contributions from recent acquisitions may have been a key driver. Productivity gains from the company’s automation and AI initiatives are likely to have favored the bottom line.
Thermo Fisher (TMO - Free Report) is also slated to report its 2026 second-quarter results before the market opens on July 23. Strength in the bioproduction and clinical research business, and the research and safety market channel may have supported the pharma and biotech end-market performance. Several recently launched high-impact innovations may have lifted revenues. The continued adoption of accelerated drug development offering is likely to have translated to share gain in its clinical research business.
ABT’s Price Performance & ValuationIn the three months ended June 30, Abbott shares have dropped 11.4%, underperforming the industry’s 10.1% decline.
Image Source: Zacks Investment Research
In terms of valuation, Abbott trades at a forward five-year Price/Earnings (P/E) of 15.93X, lower than its median of 23.28X and 16.21X industry average.
Image Source: Zacks Investment Research
EndnoteAbbott is well-positioned to benefit from strength across several of its key businesses in the second quarter of 2026, including Core Lab Diagnostics, EPD and Electrophysiology. The newly added Cancer Diagnostics portfolio is also expected to have contributed. Nutrition may have continued to navigate the near-term impact of its pricing and volume transition, with the benefits of these strategic actions expected to build over time. In the trailing four quarters, Abbott beat earnings estimates twice and came in line on two occasions.
Despite its recent underperformance, ABT is trading at a relatively cheaper valuation. Given Abbott’s strong fundamentals and diversified growth drivers, we believe existing shareholders should continue to retain their positions to enjoy long-term gains.
JPMorgan kicked off Q2 2026 earnings season this morning with a blowout earnings report that reset expectations for the entire financial sector. The bank posted $7.70 in diluted EPS versus $5.80 expected and $57.35 billion in revenue, powered by a $4.6 billion Visa share exchange gain and a 27% surge in Commercial & Investment Bank revenue. Jamie Dimon flagged IB fees up 30% to the highest level since 2021 and Markets revenue up 35%.
That combination of trading strength, capital markets reopening, and resilient consumer credit is the read-through driving peer stocks today. Here are the five names most exposed to JPMorgan’s tone-setting report, ranked by the size and directness of the impact.
1. Goldman Sachs (GS) Goldman Sachs (NYSE:GS | GS Price Prediction) is the purest read-through, and it delivered its own bombshell alongside JPM. Goldman posted EPS of $20.98 versus $14.54 expected, a 44.27% beat and its fifth straight beat. Global Banking & Markets revenue jumped 53% to $15.52 billion, with Equities up 72% and Equity Underwriting up 130%. CEO David Solomon said “Momentum has accelerated throughout our businesses… we expect this flywheel of activity to continue.”
Shares were down 0.88% intraday to $1,045.91 despite the beat, suggesting expectations were already elevated after a 20.12% YTD run. The forward catalyst is backlog conversion: management noted the IB backlog grew again versus Q1.
2. Bank of America (BAC) Bank of America (NYSE:BAC) has the closest business mix to JPMorgan, and it also reported this morning. EPS came in at $1.21 versus $1.12 expected, with Equities S&T up 70% to $3.62 billion and investment banking fees up 50%. Net interest income rose 9% YoY, and credit metrics improved with the net charge-off ratio dropping to 0.47% from 0.55%.
Brian Moynihan called it “one of our strongest quarters to date” and noted “pipelines remain strong, and commercial borrowing has picked up.” Shares rallied 2.06% to $60.73, validating the universal-bank thesis JPM anchored.
Don't wait: the analyst who called NVIDIA in 2010 just revealed his top 10 AI stocks. See the full list FREE now.
3. Morgan Stanley (MS) Morgan Stanley (NYSE:MS) has not yet reported Q2, which makes today’s peer earnings reports a direct sentiment catalyst. The stock is up 4.55% to $231.16, the largest move among the five names. Morgan Stanley’s Q1 already showed 27.1% ROTCE, Advisory up 74%, and $118.4 billion in wealth net new assets. With JPM’s IB fees at their highest since 2021 and Goldman signaling a flywheel, MS’s advisory-heavy franchise inherits the same tailwind. Ted Pick previously described the firm as reporting “a record quarter”, and the read-through raises the bar again.
4. Wells Fargo (WFC) Wells Fargo (NYSE:WFC) is the closest analog to JPM’s core banking franchise, particularly on NII and consumer credit. Shares rose 0.63% to $88.22 as JPM’s 10% NII growth and stable credit card charge-offs of 3.33% supported Wells’ outlook. Wells guided full-year 2026 NII to roughly $50 billion, and its Q1 net interest margin already compressed to 2.47% from 2.67%. The macro backdrop helps: FRED credit card delinquencies eased to 2.92%, and retail sales hit $763.7 billion in May, up 0.9% month over month. WFC remains down 4.92% YTD, so a positive read-through matters most here.
5. Visa (V) Visa (NYSE:V) is the payments proxy for JPM’s consumer spending commentary. Shares climbed 2.52% to $357.75 after JPM highlighted Card Services and Auto revenue up 12% and card annual fees up more than 30%. Visa’s most recent quarter showed payments volume up 8% and cross-border volume up 11%, and JPM’s disclosure that Chase will become the new Apple Card issuer roughly 24 months from December 2025 reinforces network volumes. Ryan McInerney described Visa as “a payments hyperscaler” driven by resilient consumer spending, the exact theme JPM validated today.
Conclusion Three themes anchor today’s cross-company read-through: capital markets have decisively reopened (GS, MS, BAC benefit most), consumer credit is stabilizing rather than deteriorating (WFC, BAC, V), and buyback capacity remains robust, with JPM authorizing a fresh $50 billion program. The primary uncertainties Dimon flagged, “geopolitical tensions and wars, sticky inflation, large global fiscal deficits and elevated asset prices,” remain the swing factors. With Morgan Stanley and Wells Fargo still to report, today’s earnings set a high bar that either extends the sector rally or exposes crowded positioning.
Don't wait: the analyst who called NVIDIA in 2010 just revealed his top 10 AI stocks. See the full list FREE now.
Charles Schwab čeká za čtvrtletí zisk 1,52 USD na akcii, tedy meziročně o 33,3 % více, při tržbách 6,75 miliardy USD (+15,4 %). Analytici navíc čekají, že firma 21. července překoná odhady.
Wall Street expects a year-over-year increase in earnings on higher revenues when The Charles Schwab Corporation (SCHW - Free Report) reports results for the quarter ended June 2026. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.
The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on July 21. On the other hand, if they miss, the stock may move lower.
While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise.
Zacks Consensus EstimateThis company is expected to post quarterly earnings of $1.52 per share in its upcoming report, which represents a year-over-year change of +33.3%.
Revenues are expected to be $6.75 billion, up 15.4% from the year-ago quarter.
Estimate Revisions TrendThe consensus EPS estimate for the quarter has been revised 2.25% higher over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.
Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change.
Price, Consensus and EPS Surprise
Earnings WhisperEstimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction).
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.
A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.
Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).
How Have the Numbers Shaped Up for Charles Schwab?For Charles Schwab, the Most Accurate Estimate is higher than the Zacks Consensus Estimate, suggesting that analysts have recently become bullish on the company's earnings prospects. This has resulted in an Earnings ESP of +2.30%.
On the other hand, the stock currently carries a Zacks Rank of #1.
So, this combination indicates that Charles Schwab will most likely beat the consensus EPS estimate.
Does Earnings Surprise History Hold Any Clue?Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.
For the last reported quarter, it was expected that Charles Schwab would post earnings of $1.39 per share when it actually produced earnings of $1.43, delivering a surprise of +2.88%.
Over the last four quarters, the company has beaten consensus EPS estimates four times.
Bottom LineAn earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.
That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
Charles Schwab appears a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
Key Takeaways Fastenal reported Q2 sales above estimates as earnings met expectations and both rose year over year.FAST benefited from contract customer growth, pricing actions and a 16.2% increase in digital sales.Gross margin narrowed, but operating margin held steady as productivity and cost leverage offset pressures. Fastenal Company (FAST - Free Report) reported mixed second-quarter 2026 results, with earnings meeting the Zacks Consensus Estimate and net sales beating the same. Conversely, year over year, both metrics grew notably.
Fastenal continued to benefit from customer signings secured since the first quarter of 2024. Contract customer daily sales increased 17.6% year over year and represented 75.8% of quarterly revenues, up from 73.2% a year earlier.
FAST stock lost 2.2% during today’s pre-market trading session after the announcement of the financial results.
Fastenal’s Q2 Earnings & Sales HighlightsFastenal’s quarterly earnings of 33 cents per share were in line with the Zacks Consensus Estimate, but increased 15.9% year over year from 29 cents per share.
Net sales rose 14.7% year over year to $2.39 billion and surpassed the consensus mark of $2.34 billion by 1.9%. Growth reflected stronger customer contract signings, pricing actions and improved industrial production. Daily sales also advanced 14.7%.
FAST’s Daily Sales Growth TrendsManufacturing daily sales increased 14.9%, with the segment contributing 75.9% of total sales. Heavy Manufacturing led the improvement with 18.1% growth and represented 44.1% of revenues. Other Manufacturing sales rose 10.8%.
Non-Residential Construction daily sales advanced 17%, marking continued growth in the market. Other End-Market sales increased 14.1%, aided by transportation and warehousing customers. Total Non-Manufacturing daily sales climbed 15.1%.
Direct-Material daily sales grew 16.5% and accounted for 39.2% of revenues. Direct Fasteners and Hardware increased 16.8%, while direct cutting tools and abrasives rose 14.8%. Direct Non-Fasteners and Hardware sales improved 16.7%.
Indirect-Material daily sales increased 14.1% and represented 60.8% of revenues. Indirect Fastener sales rose 14.6%, Safety Products increased 13.1%, and other indirect product lines advanced 14.6%. Direct materials slightly outpaced indirect products due to stronger fastener demand and manufacturing activity.
Fastenal’s Digital Sales Outpace Company GrowthDigital Footprint sales increased 16.2% to $1.49 billion and represented 61.6% of revenues, up from 61% in the prior-year quarter. The metric combines sales through Fastenal Managed Inventory technology with eBusiness sales that do not overlap with those services.
FMI sales rose 16.4% to $1.08 billion and accounted for 44.6% of revenues. FAST signed 6,993 weighted FASTBin and FASTVend devices, up 8.3%, while the installed base grew 6.5% to 140,789 units. eBusiness sales increased 12.6% to $711.9 million.
FAST Holds Operating Margin Despite PressureGross margin contracted 75 basis points (bps) to 44.6%. Unfavorable net price-cost reduced the margin by about 40 bps, while customer mix, transportation costs and rebate activity created additional pressure. Larger customers generally carry lower gross margins but produce greater profit dollars and operating efficiencies.
Selling, general and administrative expenses improved 80 bps to 23.5% of sales. Labor productivity and fixed-cost leverage offset higher incentive compensation, transportation and travel expenses. As a result, operating margin remained unchanged at 21%, while operating income increased 15.1% to $501.8 million.
Fastenal Generates Solid Cash and Returns CapitalNet income increased year over year by 15.9% to $382.8 million. Operating cash flow totaled $265.7 million, down 4.6%, and represented 69.4% of net income. Accounts receivable increased 17.6%, while inventories edged up 0.5% and accounts payable rose 25.2%.
The company returned $305.1 million to shareholders through $275.4 million in dividends and $29.7 million in share repurchases. Total debt declined to $120 million from $230 million a year ago.
FAST’s Zacks Rank & Stocks With the Favorable CombinationFastenal currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Here are some companies from the Industrial Products sector, which according to our model, have the right combination of elements to post an earnings beat in their respective quarters to be reported.
W.W. Grainger, Inc. (GWW - Free Report) has an Earnings ESP of +3.82% and a Zacks Rank of 2.
Grainger’s earnings topped the consensus mark in three of the last four quarters and missed on the remaining occasion, with the average surprise being 4.2%. Earnings for the company’s second quarter of 2026 are expected to increase 13.1% year over year.
Caterpillar Inc. (CAT - Free Report) has an Earnings ESP of +2.11% and a Zacks Rank of 2.
Caterpillar’s earnings topped the consensus mark in three of the last four quarters and missed on the remaining occasion, with the average surprise being 9.6%. Earnings for the company’s second quarter of 2026 are expected to grow 31.6% year over year.
Kennametal Inc. (KMT - Free Report) has an Earnings ESP of +45.29% and a Zacks Rank #3 (Hold).
Kennametal’s earnings topped the consensus mark in three of the last four quarters and missed on the remaining occasion, with the average surprise being 18.6%. Earnings for the company’s second quarter of 2026 are expected to surge a whopping 376.5% year over year.
Spotify spouští pro předplatitele Premium AI asistenta podobného ChatGPT, který jim na mobilu pomůže vybrat hudbu i další audio. Funkce je zatím v beta verzi v USA, Irsku a Švédsku na zařízeních s iOS a Androidem, pro uživatele od 18 let a v angličtině.
Spotify is taking another step to infuse AI technology into its listening experience, with Tuesday’s news that Premium users will now be able to have interactive conversations with the app to choose what music or other audio they want to hear.
The feature is initially available in the U.S., Ireland, and Sweden across iOS and Android devices for users 18 years old and above in English. It’s considered a beta release, meaning that things may not always work perfectly, Spotify says, but user feedback will help to improve the product.
The company didn’t explicitly share more details about the AI technology under the hood in its announcement, but Spotify confirmed to TechCrunch that it uses a mix of its own AI technology and models from multiple providers, based on whatever is best for the task.
The addition is the latest example of how Spotify has put AI technology to use to help people interact with the app’s extensive catalog of music, podcasts, and audiobooks. The company also offers tools like an AI DJ, which speaks in an AI voice that you can engage with directly, plus AI features for building playlists with prompts and those for connecting Spotify with third-party AI chatbots, like ChatGPT.
Loading the player…
The new feature extends the ability to chat with Spotify beyond the AI DJ experience, allowing users to talk to Spotify across the app’s Home and Now Playing views on mobile devices. Users can either type or speak to the app and have back-and-forth conversations to help them choose what to play next. Beyond that, Spotify says the app will also be able to chat with users about their listening history and can help them learn more about their favorite music or go deeper into podcasts or audiobooks.
That means you could get into questions like what inspired a certain song, or dates of album releases, or even get suggestions of other artists you might like, based on what you’re playing. You can also ask about your own listening history, like when was the first time you played a certain track, or you could explore more into what sort of genres you’ve been streaming lately.
In the announcement about the new feature, Spotify also offers a few suggestions as to how to use this interactive technology. For instance, you could ask Spotify to “play some artists I haven’t heard before,” then continue to shape that selection with follow-ups, like asking it to add a specific artist by name, or narrow the selection to just more recent tracks. You could also shape the request further by asking it to be “more upbeat,” or give it other directions.
Plus, you can ask Spotify to save songs, add songs to your queue, or follow the artist via the new feature.
The feature is rolling out now to the markets on mobile devices.
When you purchase through links in our articles, we may earn a small commission. This doesn’t affect our editorial independence.
Sarah has worked as a reporter for TechCrunch since August 2011. She joined the company after having previously spent over three years at ReadWriteWeb. Prior to her work as a reporter, Sarah worked in I.T. across a number of industries, including banking, retail and software.
You can contact or verify outreach from Sarah by emailing [email protected] or via encrypted message at sarahperez.01 on Signal.
Studie LEADER ukázala, že u LEQEMBI zůstalo po průměrně 17 měsících léčby stabilních nebo se zlepšilo 82,5 % pacientů s časným stadiem Alzheimerovy choroby. Z toho 75,9 % zůstalo stabilních a 6,6 % se zlepšilo. Bezpečnost byla v souladu se schváleným americkým příbalovým letákem.
Real-World Findings Support Long-Term Benefits of Continuous Treatment with LEQEMBI and Provide Important Insights into Treatment Experience Outside of a Clinical Trial Setting
, /PRNewswire/ -- Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced today that results from the real-world Lecanemab in Early Alzheimer's Disease (LEADER) Study show that nearly 83% of early Alzheimer's disease (AD) patients enrolled in the study remained stable (75.9%) or improved (6.6%) while receiving LEQEMBI® therapy over an average of 17 months. The results were consistent across sex, race, ethnicity and APOE genotype. The data was presented during the "Developing Topics Session #3-33-DEV-A: Lecanemab Three Years Post-Approval: A Comprehensive Multicenter, Real-World, Retrospective Study (LEADER) in Diverse US Clinical Settings" at the Alzheimer's Association International Conference® (AAIC®) 2026 in London and online.
AD is a chronic, progressive disease that requires ongoing treatment. LEQEMBI targets the underlying pathology of the disease and works in two ways throughout treatment - by removing insoluble (plaque) and soluble amyloid beta (protofibrils), helping to slow cognitive decline and loss of daily functioning. Data show continued treatment with LEQEMBI may be able to help keep patients in early AD for longer. Early AD includes mild cognitive impairment (MCI) due to AD and mild AD dementia.
LEADER Study Design
The three-year LEADER Study is a multicenter, retrospective real-world study designed to examine LEQEMBI utilization, treatment persistence, transition to maintenance therapy, safety, cognitive and functional assessments, and healthcare professional (HCP) implementation learnings in diverse U.S. clinical settings for patients with early Alzheimer's disease (AD). The study integrated deidentified chart and electronic medical record (EMR) data from 13 U.S. sites, HCP surveys and HCP interviews. This interim analysis included 432 patients with early AD who received at least seven LEQEMBI infusions as of May 2026.
Patient Characteristics at Baseline
Mean age: 74 years Female Patients: 55.8% Disease Stage at Baseline
Mild cognitive impairment (MCI) due to AD: 63.9% Mild AD dementia: 36.1%. Treatment
The mean duration of LEQEMBI treatment was 520 days. The mean number of LEQEMBI doses was 26. Change in disease stage was defined as: Stable: Patient remaining in the same disease stage (MCI due to AD or mild AD dementia) from baseline throughout the course of LEQEMBI treatment. Improvement: Patient transitioning from mild AD dementia at baseline to MCI due to AD over the course of LEQEMBI treatment. Progression: Patient advancing from MCI at baseline to mild/moderate AD dementia or from mild AD dementia at baseline to moderate AD dementia throughout the course of LEQEMBI treatment. LEADER Study Key Findings
Real-World Evidence Shows Long-Term Benefit with Continuous LEQEMBI Treatment Across Sex, Race, Ethnicity and APOE Genotype
Overall Study Population Findings
Of the 432 participants enrolled in the LEADER Study, disease stage could be evaluated in 427. Among these patients with early Alzheimer's disease, 82.5% remained stable or improved while receiving LEQEMBI, with consistent results across sex, race, ethnicity, and APOE genotype groups. 75.9% remained stable compared with baseline, meaning they remained in the same disease stage throughout treatment. 6.6% improved from baseline, moving from mild AD dementia to MCI due to AD. Nearly 87% of patients chose to remain on LEQEMBI treatment. In analyses by APOE ε4 status, clinician-evaluated stable or improved disease stage was observed in: 81.7% of APOE ε4 heterozygotes (stable: 73.8%; improved: 7.9%) 81.0% of APOE ε4 homozygotes (stable: 75.9%; improved: 5.2%). Maintenance Dosing Population Findings
Of the 432 participants in the LEADER Study, 155 transitioned to once-every-four-weeks intravenous (IV) maintenance treatment, and 14 transitioned to once-weekly subcutaneous (SC) maintenance treatment. Among the 155 participants who transitioned to IV maintenance therapy, nearly 81% remained stable (72.3%) or improved (8.4%). Of the 14 patients who transitioned to SC maintenance treatment, 12 (85.7%) maintained their disease stage. Real-World Safety Consistent with U.S. FDA-Approved Label
Overall safety observations in this real-world study were consistent with the U.S. FDA-approved label.
ARIA (amyloid-related imaging abnormalities)* was observed in 12.3% of patients overall; ARIA-E was observed in 6.3% and ARIA-H in 7.9% and isolated ARIA-H in 6.0%. Most ARIA cases were asymptomatic and mild in radiographic severity. No new ARIA-E events, macrohemorrhages or intracerebral hemorrhages greater than 1 cm were reported during once-every-four-weeks IV maintenance therapy. APOE ε4 status safety observations were consistent with the overall cohort and the U.S. FDA-approved label.
ARIA-E was observed in 5.3% of APOE ε4 noncarriers, 6.1% of APOE ε4 heterozygotes and 10.3% of APOE ε4 homozygotes. ARIA-H was observed in 12.1%, 4.8% and 12.1%, respectively. In APOE ε4 homozygotes, no severe ARIA was reported, and all graded ARIA cases were mild to moderate in radiographic severity. Antithrombotic therapy, including anticoagulants or antiplatelet medications, was used by 106 patients, representing 24.5% of the study population.
Of these, 11 patients were receiving an anticoagulant, either alone or with an antiplatelet medication, and 95 patients were receiving antiplatelet therapy only. Among patients receiving antithrombotic therapy, the incidence of ARIA was not meaningfully different from that observed in patients not receiving antithrombotic therapy. * ARIA refers to amyloid-related imaging abnormalities that can be observed with anti-amyloid beta antibody treatment and includes ARIA-E, which involves edema/effusion, and ARIA-H, which involves hemosiderin deposition, including cerebral microhemorrhage, cerebral macrohemorrhage and superficial siderosis, as observed on brain magnetic resonance imaging (MRI).
Eisai serves as the lead for lecanemab's development and regulatory submissions globally with Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority.
MEDIA CONTACTS
Eisai Co., Ltd.
Public Relations Department
TEL: +81 (0)3-3817-5120
Eisai Europe, Ltd.
EMEA Communications Department
+44 (0)7760 619251
[email protected]
Eisai Inc. (U.S.)
Julie Edelman
+1-862-213-5915
[email protected]
Biogen Inc.
Madeleine Shin
+1-781-464-3260
[email protected]
INVESTOR CONTACTS
Eisai Co., Ltd.
Investor Relations Department
TEL: +81 (0) 3-3817-5122
Biogen Inc.
Tim Power
+1-781-464-2442
[email protected]
Notes to Editors
About lecanemab (generic name, brand name: LEQEMBI®)
Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ).
Lecanemab has been approved in 53 countries and regions including Japan, the United States, China, Europe, South Korea, Taiwan, and Saudi Arabia, and is under regulatory review in 6 countries. Following the initial phase with treatment every two weeks for 18 months, intravenous (IV) maintenance dosing with treatment every four weeks was approved in 8 countries including the U.S., China, the UK, and others, and applications have been filed in 12 countries and regions. The U.S. FDA approved LEQEMBI IQLIK, the subcutaneous autoinjector formulation of lecanemab, for use as maintenance treatment in August 2025 and as initiation treatment on July 13, 2026. In November 2025, an application for a subcutaneous injectable formulation in Japan was submitted. In January 2026, the Biologics License Application (BLA) for the subcutaneous formulation was accepted in China. Since December 2025, lecanemab (IV) has been included in the "Commercial Insurance Innovative Drug List", recently introduced by the National Healthcare Security Administration (NHSA) of China.
Since July 2020, the Phase 3 clinical study (AHEAD 3-45) for individuals with preclinical AD, meaning they are clinically normal and have intermediate or elevated levels of amyloid in their brains, is ongoing. AHEAD 3-45 is conducted as a public-private partnership between the Alzheimer's Clinical Trial Consortium that provides the infrastructure for academic clinical trials in AD and related dementias in the U.S., funded by the National Institute on Aging, part of the National Institutes of Health, Eisai and Biogen. Since January 2022, the Tau NexGen clinical study for Dominantly Inherited AD (DIAD), that is conducted by Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in St. Louis, is ongoing and includes lecanemab as the backbone anti-amyloid therapy.
About Protofibrils
Protofibrils are thought to be the most toxic Aβ species that contribute to brain damage in AD and play a major role in the cognitive decline of this progressive and devastating disease. Protofibrils can cause neuronal and synaptic damage in the brain, which can subsequently adversely affect cognitive function through multiple mechanisms.1 The mechanism by which this occurs has been reported not only by increasing the formation of insoluble Aβ plaques, but also by directly damaging signaling between neurons and other cells. It is believed that reducing protofibrils may reduce neuronal damage and cognitive impairment, potentially preventing the progression of AD.2
Limitations of Real-World Studies
Retrospective real-world studies can be valuable in providing additional information to complement clinical trial data; however, there are potential limitations to consider, including: potential for biases, data completeness and consistency, lack of a control group, interpretation of data due to lack of placebo-controlled arms, and confounding variables, and data inconsistency. Data inconsistency may be mitigated by providing site access to standardized electronic case-report forms.
About the Collaboration between Eisai and Biogen for AD
Eisai and Biogen have been collaborating on the joint development and commercialization of AD treatments since 2014. Eisai serves as the lead of LEQEMBI development and regulatory submissions globally with both companies co-commercializing and co-promoting the product and Eisai having final decision-making authority.
About the Collaboration between Eisai and BioArctic for AD
Since 2005, Eisai and BioArctic have had a long-term collaboration regarding the development and commercialization of AD treatments. Eisai obtained the global rights to study, develop, manufacture and market lecanemab for the treatment of AD pursuant to an agreement with BioArctic in December 2007. The development and commercialization agreement on the antibody lecanemab back-up was signed in May 2015.
About Eisai Co., Ltd.
Eisai's Corporate Concept is "to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides." Under this Concept (also known as human health care (hhc) Concept), we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology.
In addition, we demonstrate our commitment to the elimination of neglected tropical diseases (NTDs), which is a target (3.3) of the United Nations Sustainable Development Goals (SDGs), by working on various activities together with global partners.
For more information about Eisai, please visit www.eisai.com (for global headquarters: Eisai Co., Ltd.), and connect with us on X, LinkedIn and Facebook. The website and social media channels are intended for audiences outside of the UK and Europe. For audiences based in the UK and Europe, please visit www.eisai.eu and Eisai EMEA LinkedIn.
About Biogen
Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients' lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth.
The company routinely posts information that may be important to investors on its website at www.biogen.com. Follow Biogen on social media – Facebook, LinkedIn, X, YouTube.
Biogen Safe Harbor
This news release contains forward-looking statements, including about the potential clinical effects of lecanemab; the potential benefits, safety and efficacy of lecanemab; potential regulatory discussions, submissions and approvals and the timing thereof including for lecanemab-irmb (LEQEMBI IQLIK); the treatment of Alzheimer's disease; the anticipated benefits and potential of Biogen's collaboration arrangements with Eisai; the potential of Biogen's commercial business and pipeline programs, including lecanemab; and risks and uncertainties associated with drug development and commercialization. These forward-looking statements may be accompanied by such words as "aim," "anticipate," "assume," "believe," "contemplate," "continue," "could," "estimate," "expect," "forecast," "goal," "guidance," "hope," "intend," "may," "objective," "plan," "possible," "potential," "predict," "project," "prospect," "should," "target," "will," "would," and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements. Given their forward-looking nature, these statements involve substantial risks and uncertainties that may be based on inaccurate assumptions and could cause actual results to differ materially from those reflected in such statements.
These forward-looking statements are based on management's current beliefs and assumptions and on information currently available to management. Given their nature, we cannot assure that any outcome expressed in these forward-looking statements will be realized in whole or in part. We caution that these statements are subject to risks and uncertainties, many of which are outside of our control and could cause future events or results to be materially different from those stated or implied in this document, including, among others, uncertainty of long-term success in developing, licensing, or acquiring other product candidates or additional indications for existing products; expectations, plans and prospects relating to product approvals, approvals of additional indications for our existing products, sales, pricing, growth, reimbursement and launch of our marketed and pipeline products; our ability to effectively implement our corporate strategy; the successful execution of our strategic and growth initiatives, including acquisitions; the risk that positive results in a clinical trial may not be replicated in subsequent or confirmatory trials or success in early stage clinical trials may not be predictive of results in later stage or large scale clinical trials or trials in other potential indications; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates; the occurrence of adverse safety events, restrictions on use with our products, or product liability claims; and any other risks and uncertainties that are described in other reports we have filed with the U.S. Securities and Exchange Commission, which are available on the SEC's website at www.sec.gov.
These statements speak only as of the date of this press release and are based on information and estimates available to us at this time. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected. Investors are cautioned not to put undue reliance on forward-looking statements. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and in our subsequent reports on Form 10-Q, Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements whether as a result of any new information, future events, changed circumstances or otherwise.
Digital Media Disclosure
From time to time, we have used, or expect in the future to use, our investor relations website (investors.biogen.com), the Biogen LinkedIn account (linkedin.com/company/biogen-) and the Biogen X account (https://x.com/biogen) as a means of disclosing information to the public in a broad, non-exclusionary manner, including for purposes of the SEC's Regulation Fair Disclosure (Reg FD). Accordingly, investors should monitor our investor relations website and these social media channels in addition to our press releases, SEC filings, public conference calls and websites, as the information posted on them could be material to investors.
References
Amin L, Harris DA. Aβ receptors specifically recognize molecular features displayed by fibril ends and neurotoxic oligomers. Nat Commun. 2021;12:3451. doi:10.1038/s41467-021-23507-z Ono K, Tsuji M. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease. Int J Mol Sci. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706. SOURCE Eisai Inc.
Mondelez ve fiskálním 1. čtvrtletí 2026 zvýšil organické čisté tržby v sušenkách a pečených snackech o 1,7 %. Novinka Ritz Drizzled pomohla značce Ritz získat od začátku roku 0,2 procentního bodu podílu na trhu.
Key Takeaways Biscuits and baked snacks posted 1.7% organic net revenue growth in the first quarter of 2026. Ritz Drizzled helped the brand gain 0.2 percentage points of market share year to date. Mondelez is expanding distribution in emerging markets and convenience, club and online channels. Mondelez International, Inc. (MDLZ - Free Report) is relying on its biscuit portfolio to support sales growth, with Oreo and Ritz continuing to play an important role in the category. The company's strategy combines established brands with product innovation and broader distribution as it works to strengthen its biscuits business across markets.
The approach delivered encouraging results in the first quarter of 2026. Biscuits and baked snacks, which represented 48% of fiscal 2025 net revenues, generated organic net revenue growth of 1.7%, supported by a 0.6-percentage-point improvement in volume and mix. Oreo and Ritz were among the brands that posted growth during the quarter, while the U.S. biscuit business returned to slight growth after showing sequential improvement.
Innovation remains an important part of that effort. During the quarter, Mondelez introduced Ritz Drizzled, a sweet-and-salty extension of its Ritz crackers featuring fudge or caramel coating. The company said the launch helped the Ritz brand gain 0.2 percentage points of market share year to date. Oreo also featured in the company's innovation lineup with Oreo Minis.
Alongside innovation, Mondelez is expanding distribution in emerging markets and increasing its presence in under-indexed developed-market channels, including convenience, club and online, where these channels contributed to improved U.S. biscuit volume performance on a sequential basis.
The first-quarter performance indicates that Oreo and Ritz continue to support Mondelez's biscuits business through a combination of brand growth, innovation and wider distribution. At the same time, the company noted that the U.S. biscuit category remains soft, although its own biscuit business has shown signs of stabilization. Continued execution across these initiatives will be important in supporting future sales growth for the category.
MDLZ Stock Price Performance, Valuation & EstimatesShares of Mondelez International have tumbled 11.5% over the past year compared with the industry’s decline of 21.9%. MDLZ currently carries a Zacks Rank #3 (Hold).
MDLZ Price Performance Versus Industry
Image Source: Zacks Investment Research
From a valuation standpoint, MDLZ trades at a forward price-to-earnings ratio of 18.49, higher than the industry’s average of 14.55.
MDLZ Valuation Compared to Industry
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for MDLZ’s current and next fiscal-year earnings per share implies year-over-year growth of 4.5% and 11.3%, respectively.
Better-Ranked Stocks to ConsiderUnited Natural Foods, Inc. (UNFI - Free Report) , a major food wholesaler serving grocery retailers, currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for United Natural’s current and next fiscal-year earnings per share suggests a year-over-year increase of 254.9% and 21.4%, respectively. UNFI delivered a trailing four-quarter earnings surprise of 29.9%, on average.
Mama's Creations, Inc. (MAMA - Free Report) , a maker of refrigerated prepared foods for retail and foodservice, carries a Zacks Rank #2 (Buy) at present.
The Zacks Consensus Estimate for Mama's Creations’ current and next fiscal-year EPS implies growth of 73.3% and 46.2%, respectively, from the prior-year reported levels. MAMA delivered a trailing four-quarter earnings surprise of 129.2%, on average.
Hormel Foods Corporation (HRL - Free Report) , a global branded food company offering meat, protein and packaged food products, carries a Zacks Rank #2.
The Zacks Consensus Estimate for Hormel Foods’ current and next fiscal-year EPS calls for a year-over-year jump of 9.5% and 3.5%, respectively. HRL delivered a trailing four-quarter earnings surprise of 3.2%, on average.
Paramount Skydance stále usiluje o dokončení akvizice Warner Bros. Discovery do konce září, i když proti dohodě podali žalobu státní zástupci kvůli antimonopolním obavám.
Paramount Skydance is still aiming to close its proposed acquisition of Warner Bros. Discovery by the end of September despite a recent lawsuit filed by state attorneys general challenging the deal, Paramount's lead trial counsel Jeffrey Kessler told CNBC's David Faber in an interview on Tuesday.
On Monday, a group of state attorneys general led by California's Rob Bonta filed a lawsuit aimed at blocking the merger due to antitrust concerns. Later in the day, the group filed court papers seeking a temporary restraining order to put the deal on hold so that legal proceedings could move forward.
Either way, Kessler said that the company is prepared to bring the matter to the Supreme Court if it faced a prolonged blockade in closing the deal.
"The company believes strongly in this," Kessler said of the combination of the entertainment and media companies.
Kessler told Faber on Tuesday the temporary restraining order came after Paramount "indicated" that its intention was to be able to close as early as July 22, when the company expects to have all regulatory clearances.
The July date stems from the next big hurdle Paramount needs to clear. The European Union has been reviewing the deal for approval and recently set July 22 as a new provisional deadline. Paramount recently submitted concessions to the EU as it looks to smooth concerns regarding the deal.
The proposed acquisition that would bring together the two storied film studios of Warner Bros. and Paramount, as well as a sprawling portfolio of pay TV networks, has already received approval from the Antitrust Division of the U.S. Department of Justice, as well as other global jurisdictions.
"Or we could work out a schedule to get this all decided by early September, that would be perfectly acceptable to the company if we could create an orderly procedure," Kessler said. "The states rejected both alternatives so right now we have a [temporary restraining order] that's been filed."
If granted, it would pause the deal for 14 days. Up to two temporary restraining orders could be granted before the coalition seeks a preliminary injunction, putting the deal on ice while it's sorted out in court. Kessler said on Tuesday the company doesn't expect it to get to that point, arguing this isn't an antitrust issue.
A long delay could be costly for Paramount. As part of the deal, Paramount has agreed to pay a so-called ticking fee, meaning that if the closing goes past Sept. 30, Paramount would pay additional fees to WBD shareholders per quarter until closing. That fee would equal roughly $650 million in cash value per quarter.
For it to be delayed or blocked, "the merger has to be anti-competitive. This merger is pro-competitive," Kessler told Faber.
"Anybody who knows the entertainment industry knows it is in deep trouble," he added, noting widespread challenges as consumers flee pay TV bundles and competition among streaming giants like Netflix intensifies.
He added that the merger would create a competitor that could "go toe to toe with a Netflix or Disney or [Amazon's] Prime," which would be a positive for the theater industry and Hollywood workers.
On Monday, Bonta said in a release that the merger would "lead to higher prices, lower quality, and less content for film and television, harming movie theaters, basic cable distributors, and ultimately, audiences on every sofa and movie theater seat in the U.S."
As Hollywood has expressed concerns since the deal was announced, Paramount CEO David Ellison has promised that once merged, the film studios would together put out a slate of 30 movies annually.
"We've told the states if they have what they think are legitimate concerns, they should come to the table and we talk about them," said Kessler, noting the question of whether Paramount could deliver the 30 films per year.
Kessler said that Paramount has told state attorneys general the company is willing to put in writing that it would commit to the 30 films, and if it doesn't happen, litigation could then take place.
Společnost Ark Invest Cathie Woodové prodala akcie BioNTech za zhruba 7,4 milionu USD a zůstalo jí jen 307 kusů. Akcie BioNTech letos klesly téměř o 4 % a za 12 měsíců o více než 17 %.
On July 7, Cathie Wood's Ark Genomic Revolution ETF (ARKG +0.39%) sold over 44,000 shares of BioNTech (BNTX 0.32%), a German immunotherapy maker. The next day, it sold over 78,000 shares, a transaction valued at around $7.4 million.
As of July 10, that left her asset management company with just 307 shares, valued at a little more than $28,000. Because Ark Invest holds positions worth millions of dollars and BioNTech is now the smallest holding in this entire exchange-traded fund (ETF), it may be fair to assume that Wood has moved on from BioNTech.
Image source: Getty Images.
What may have caused BioNTech to get the boot One thing to know about ARKG is that it's an actively managed ETF, so it's common for the fund to move in and out of stocks frequently.
Today's Change
(
0.39
%) $
0.16
Current Price
$
40.75
Because Wood's ETF has now sold most of its BioNTech shares, it appears to be moving on, freeing up capital for Ark Invest. BioNTech stock has underperformed this year; as of this writing, its price is down nearly 4% year to date and has dipped more than 17% over the last 12 months. But there are challenges ahead that could continue to send shares lower.
One is that revenue is expected to land somewhere between 2 billion euros ($2.2 billion) and 2.3 billion euros ($2.6 billion) in 2026, a significant decrease from the 2.9 billion euros ($3.3 billion) reported for 2025. That's largely due to an expected drop in revenue from its COVID-19 vaccine, developed in partnership with Pfizer.
Another financial issue is that BioNTech reported back-to-back net losses in 2024 and 2025, after a net profit of 900 million euros ($1 billion) in 2023. That trend of net losses will likely continue, as BioNTech already showed a net loss in its 2026 first-quarter earnings report.
There are also issues on the leadership front. BioNTech's co-founders, Uğur Şahin and Özlem Türeci, are leaving the company by the end of 2026. Şahin is the CEO, and Türeci is the chief medical officer, so those are significant roles to fill. What makes that leadership transition even more challenging is that BioNTech has been shifting its focus from vaccines to oncology treatments.
Today's Change
(
-0.32
%) $
-0.29
Current Price
$
89.79
Is it time to sell BioNTech? The move from Ark Invest is notable. While investors shouldn't automatically follow its lead in selling the stock, BioNTech is trying to overcome several challenges at once. The company has a promising clinical pipeline of more than 25 phase 2 or phase 3 trials in oncology, but it only has one commercial product -- that COVID vaccine with slumping sales. All of this is complicated by the need to find new leadership.
If you haven't invested yet, you may want to consider holding off on starting a position -- at least until new management is found and the drugs in the pipeline show more progress.
Společnost Kratos Defense rozšiřuje výrobu, aby podpořila vyšší objemy obranné produkce a budoucí programy USA i spojenců. Investuje do raket, radarů, elektronického boje, C5ISR a hypersonických systémů.
Key Takeaways Kratos Defense is expanding manufacturing to support higher defense production volumes and future programs.KTOS is investing across missile, radar, electronic warfare, C5ISR and hypersonic production capabilities.KTOS trades below the industry's forward P/S average despite expanded domestic manufacturing investments. Kratos Defense & Security Solutions, Inc. (KTOS - Free Report) is investing in manufacturing infrastructure to support higher production volumes rather than relying solely on the development of advanced technologies. Management believes that expanding production capacity today is critical to meeting the growing demand anticipated from future U.S. and allied defense programs.
To support this strategy, Kratos Defense continues to invest across multiple business segments, including Defense Rocket Systems, Turbine Technologies, Microwave Electronics, C5ISR and Hypersonic Systems. The company is expanding manufacturing facilities, increasing engineering resources, and enhancing production capabilities to support programs involving missile propulsion, affordable cruise missiles, radar systems, electronic warfare, and next-generation defense technologies. These investments are intended to improve production readiness while enabling the company to compete for larger, long-duration contracts.
Another important pillar of KTOS' strategy is strengthening the domestic defense supply chain. As governments seek to reduce reliance on foreign suppliers for critical defense technologies, Kratos Defense's vertically integrated manufacturing model and U.S.-based operations provide greater control over production, quality and delivery schedules. This positions the company to support the Pentagon's broader objective of creating a more resilient and responsive industrial base capable of sustaining long-term military readiness.
As global defense spending continues to rise and the U.S. prioritizes rebuilding its industrial capacity, companies with scalable domestic manufacturing capabilities are likely to become increasingly important partners for the Department of Defense. By expanding production capacity and strengthening its supply chain, KTOS appears well positioned to benefit from one of the most significant defense modernization cycles in decades.
Defense Companies Benefiting From Similar TrendsSeveral other defense companies are also investing in expanding domestic manufacturing and production capacity, including:
RTX Corporation (RTX - Free Report) is increasing production of missile systems, air defense technologies, and advanced sensors to meet growing global demand.
Northrop Grumman (NOC - Free Report) continues to invest in facilities that support missile defense, strategic deterrence, space systems, and advanced propulsion technologies, helping strengthen the U.S. defense industrial base.
KTOS Stock’s Earnings EstimatesThe Zacks Consensus Estimate for 2026 earnings per share indicates an increase of 30.91% year over year.
Image Source: Zacks Investment Research
KTOS Stock Trades at a DiscountIn terms of valuation, KTOS’ forward 12-month price-to-sales (P/S) is 4.5X, a discount to the industry’s average of 8.67X.
Image Source: Zacks Investment Research
KTOS Stock’s Price PerformanceIn the past six months, KTOS’ shares have lost 62.3% compared with the industry’s 7.8% decline.
Wheaton Precious Metals vykázala v 1. čtvrtletí rekordní provozní peněžní tok 766 mil. USD, oproti 361 mil. USD před rokem. Potvrdila také výhled produkce na rok 2026 na 860 000–940 000 GEOs.
Key Takeaways Wheaton Precious Metals delivered a record Q1 operating cash flow of $766 million on a higher gross margin.WPM reaffirmed its 2026 guidance of 860,000-940,000 GEOs, with output weighted to the second half.Wheaton Precious Metals expects $10B in operating cash flow in 2026-2028 at base case prices. Wheaton Precious Metals Corp. (WPM - Free Report) reported a record operating cash flow of $766 million in the first quarter of 2026 compared with $361 million in the year-ago quarter. The upside was driven by a higher gross margin.
Wheaton Precious Metals had $2.16 billion in cash in hand at the end of the first quarter of 2026 compared with $1.15 billion at the end of 2025. After delivering record annual dividends of 66 cents per share in 2025, the company raised its first-quarter 2026 dividend 18% to 19.5 cents from the fourth quarter of 2025.
In the first quarter of 2026, gold-equivalent production rose 21.5% to 211,951 ounces, reflecting stronger output from Salobo and Peñasquito, Antamina and Blackwater, along with the recommencement of production at Aljustrel.
The company reaffirmed its 2026 attributable production guidance of 860,000-940,000 GEOs, with output expected to be weighted to the second half as Antamina’s added stream contributes from the second quarter and several newer mines continue ramping. The company expects production of 1.2 million GEOs by 2030, incorporating additional incremental production from the pre-development assets.
Anticipated production growth, driven by mine performances, along with the solid rally in gold prices, sets a positive outlook for the company's cash flow generation. Backed by this, the company expects to generate $10 billion in operating cash flow from 2026 to 2028 at base case commodity prices.
Recent Performances of Wheaton Precious Metals’ PeersSSR Mining Inc. (SSRM - Free Report) reported a free cash flow of $211 million for the first quarter of 2026. The company produced 109,914 gold equivalent ounces, which came within SSRM’s guidance. SSR Mining had produced 103,805 gold equivalent ounces in the year-ago quarter.
For 2026, SSR Mining expects gold-equivalent production of 450,000-535,000 ounces, indicating a year-over-year increase of 10% at the midpoint.
AngloGold Ashanti PLC (AU - Free Report) delivered a record $1.2 billion in free cash flow in the first quarter of 2026, a 190% year-over-year whopping rise. The upside is driven by AngloGold Ashanti’s continued cost discipline, steady production and higher gold prices. AngloGold Ashanti’s gold production in the first quarter increased 1% year over year.
AngloGold Ashanti’s gold production for 2026 is projected at 2.80-3.17 million ounces. This suggests a year-over-year dip of 3% at the midpoint.
WPM’s Price Performance, Valuation & EstimatesWheaton Precious Metals shares have gained 18.7% in a year compared with the industry's 36.3% growth. In comparison, the Zacks Basic Materials sector and the S&P 500 have returned 24.6% and 25.8%, respectively.
Image Source: Zacks Investment Research
WPM is currently trading at a forward 12-month price-to-earnings multiple of 22.57X, a premium to the industry average of 14.28X.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Wheaton Precious Metals’ 2026 sales is $3.71 billion, indicating a 60.4% year-over-year jump. The consensus mark for the year’s earnings is pegged at $4.78 per share, suggesting a year-over-year rally of 57.8%.
The Zacks Consensus Estimate for 2027 sales implies a 1.8% year-over-year rise. The same for earnings suggests a dip of 0.1%.
EPS estimates for 2026 have moved south, while the estimates for 2027 have moved north over the past 60 days.
Image Source: Zacks Investment Research
WPM currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Hemp-derived THC beverages, including the new zero-proof Mixer, roll out to liquor retailers statewide
, /PRNewswire/ -- cbdMD, Inc. (NYSE American: YCBD) today announced that its Oasis line of hemp-derived beverages is now available in South Carolina through a new distribution agreement with Morales Beverage Group, South Carolina, a leading beverage statewide alcohol distributor. The agreement places Oasis products on liquor store shelves across the state, giving South Carolina consumers direct access to the brand at established retail destinations.
The rollout includes the the full Oasis portfolio, featuring the brand's newest release, the zero proof spirit style Mixer, a spirit-style hemp-derived beverage designed for consumers looking for a versatile option for cocktails and mixed drinks. Oasis products are now stocked at retailers throughout South Carolina, including Frugal MacDoogal, one of the Carolinas' best-known beverage destinations.
"South Carolina is an important market for Oasis, and Mexcor is the right partner to help us reach consumers where they already shop for spirits, wine, and beer," said Ronan Kennedy, CEO of cbdMD. "Getting Oasis, and especially Mixer, onto liquor store shelves alongside traditional beverage alcohol is exactly the kind of placement that introduces the brand to a broader audience."
"Its always a challenge as a distributor to make decisions on what new products to bring to the market. The team at Herbal Oasis made it very easy. A well-established company from the Carolinas, proven sales in other markets, and quality and innovation that is out pacing the industry. It was an easy yes! I'm very excited to be representing this brand in the state of South Carolina", said Adam Howard, General Manager of MGB South Carolina.
Placing Oasis within the established liquor retail channel reflects the brand's strategy of meeting adult consumers in familiar shopping environments and positioning hemp-derived beverages as an approachable option within the broader beverage category. Mexcor's distribution network and retail relationships across South Carolina provide a foundation for expanding availability over time.
Oasis products are crafted to quality and testing standards consistent with cbdMD's broader commitment to transparency and responsible product development. All Oasis products are intended for adults of legal purchasing age.
About cbdMD, Inc.
cbdMD, Inc. (NYSE American: YCBD) is a consumer wellness company building a multi-brand platform across hemp-derived wellness, beverages, pet wellness, botanical wellness, and related consumer categories. Its portfolio includes cbdMD, Paw CBD, Oasis, and Bluebird Botanicals. For more information, visit www.cbdmd.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding product distribution, retail availability, market expansion, consumer demand, and the Company's beverage strategy. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including risks related to distribution and retail relationships, evolving federal and state regulation of hemp-derived products, the Company's ability to maintain regulatory compliance, and other risks described in the Company's filings with the Securities and Exchange Commission. The Company undertakes no obligation to update forward-looking statements except as required by law.
Contacts
cbdMD, Inc.
Ronan Kennedy
Chief Executive Officer and Chief Financial Officer
Capital One (COF - Free Report) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended June 2026. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.
The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on July 21. On the other hand, if they miss, the stock may move lower.
While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise.
Zacks Consensus EstimateThis credit card issuer and bank is expected to post quarterly earnings of $4.89 per share in its upcoming report, which represents a year-over-year change of -10.8%.
Revenues are expected to be $15.69 billion, up 25.6% from the year-ago quarter.
Estimate Revisions TrendThe consensus EPS estimate for the quarter has been revised 0.41% higher over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.
Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change.
Price, Consensus and EPS Surprise
Earnings WhisperEstimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. Our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction) -- has this insight at its core.
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.
A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.
Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).
How Have the Numbers Shaped Up for Capital One?For Capital One, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. This has resulted in an Earnings ESP of -1.95%.
On the other hand, the stock currently carries a Zacks Rank of #3.
So, this combination makes it difficult to conclusively predict that Capital One will beat the consensus EPS estimate.
Does Earnings Surprise History Hold Any Clue?While calculating estimates for a company's future earnings, analysts often consider to what extent it has been able to match past consensus estimates. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.
For the last reported quarter, it was expected that Capital One would post earnings of $4.61 per share when it actually produced earnings of $4.42, delivering a surprise of -4.12%.
Over the last four quarters, the company has beaten consensus EPS estimates two times.
Bottom LineAn earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.
That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
Capital One doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
Warren Buffett urychluje dary akcií Berkshire Hathaway čtyřem rodinným nadacím a chce se zbavit všech svých podílů zhruba do osmi let, tedy do 31. prosince 2034. Gates Foundation už další dary nedostane.
(This is a special breaking news edition of the Warren Buffett Watch newsletter, news and analysis on all things Warren Buffett and Berkshire Hathaway. You can sign up here to receive it every Friday evening in your inbox.)
BUFFETT ACCELERATES DONATIONSSETS GOAL TO 'DISPOSE OF ALL' HIS SHARES IN EIGHT YEARSGIVES $6B TO FOUR FAMILY FOUNDATIONSGATES FOUNDATION CUT OFFBUFFETT ON CNBC'S 'SQUAWK' WEDNESDAY MORNINGWarren Buffett is speeding up the pace of his annual donations of Berkshire Hathaway shares to four family foundations, giving them a total of almost $6 billion now.
In a news release this morning, Buffett says, "My goal is to dispose of all of my Berkshire shares within about eight years."
CNBC's Becky Quick is sitting down with Buffett in Omaha and we will bring you that interview starting at 6 am ET tomorrow (Wednesday) on "Squawk Box."
Buffett, who will be celebrating his 96th birthday next month, now owns stock in the company with a market value of more than $140 billion.
Even without taking into account potential increases in Berkshire's stock price, that implies gifts of at least $17 billion each year, more than double the $7 billion in stock he donated last year.
In the release, Buffett says, "Of course, mortality is unpredictable, but my remaining shares will be donated to the four foundations one way or the other by December 31, 2034."
That excludes the Gates Foundation from any further donations, ending what Buffett said in 2006 would be a "lifetime pledge" of annual gifts to the charity established by Microsoft co-founder Bill Gates and his then-wife, Melinda Gates.
Based on the schedule he set out at that time in which the number of shares decreased by 5% each year, he was due to donate almost $4.5 billion to the Gates Foundation this month.
watch now
Last year around this time, Buffett gave the four family foundations around $1.4 billion in gifts, so it appears this year they are also getting the donation originally earmarked for the Gates group.
In this round, Buffett is giving the Susan Thompson Buffett Foundation, named for his late first wife, 9 million Class B shares with a current value of around $4.5 billion.
The three foundations run by his children, Susie Buffett's Sherwood Foundation, the Howard G. Buffett Foundation, and Peter Buffett's NoVo Foundation, will each get 1 million Class B shares worth just under $500 million.
The release does not say whether he will also be making gifts to the family foundations at Thanksgiving as he has done in the last four years, but it seems likely given his new eight-year goal.
Last year those contributions totaled around $1.3 billion.
Earlier this month, The Wall Street Journal reported Buffett was holding back his scheduled donation to the Gates Foundation pending a law firm's review of the charity's ties to Jeffrey Epstein, with the results expected this summer.
In 2006, Buffett said he was "irrevocably committing to make annual gifts of Berkshire Hathaway 'B' shares throughout my lifetime" for the Gates Foundation's benefit as long as either Bill or Melinda Gates "remain alive and active in [its] policy-setting and administration."
But cracks in what had been a strong personal friendship with Bill Gates began to appear in 2021, when Buffett resigned as a foundation trustee two months after Bill and Melinda announced they had decided to end their 27-year marriage.
In 2024, Buffett told the Journal, "The Gates Foundation has no money coming after my death," following a revision of his will that made his three children the trustees of a charitable trust that will hold "99%-plus" of his wealth.
This year, revelations in the Jeffrey Epstein files about the notorious pedophile's connections to Gates put even more strain on Buffett's relationship with Microsoft's co-founder.
In March, Buffett told CNBC he has not talked to Gates "at all since the whole thing was unveiled" and "until it gets cleared up ... I just don't think it makes sense to do a lot of talking."
Asked whether we will continue to give money to the Gates Foundation, Buffett replied, "I'll wait and see what unfolds ... I don't have to make that decision today. And I haven't made it today."
"I've learned things I didn't know about something for all these years."
Over the last two decades, Buffett's Gates Foundation gifts have totaled almost $48 billion, based on the value of the shares when they were donated.
The current value of the almost 321 million shares donated to the charity is around $159 billion.
It has sold the vast majority of them over the years to help fund its operations.
QUESTIONS OR COMMENTSPlease send any questions or comments about the newsletter to me at [email protected]. (Sorry, but we don't forward questions or comments to Buffett himself.)
If you aren't already subscribed to this newsletter, you can sign up here.
Also, Buffett's annual letters to shareholders are highly recommended reading. There are collected here on Berkshire's website.
USD/CNY slipped below 6.78 after the People's Bank of China set another stronger-than-expected daily fixing, reinforcing support for the Chinese yuan. Markets see the PBOC allowing gradual yuan appreciation while avoiding excessive volatility through its daily reference rate and liquidity operations. Traders are now watching whether USD/CNY can break below 6.75 or rebound toward the 6.80 resistance zone as US inflation and Federal Reserve expectations remain in focus. The USD/CNY exchange rate edged lower on Tuesday as the Chinese yuan strengthened after another closely watched currency fixing from the People’s Bank of China (PBOC). The move reinforced expectations that policymakers remain comfortable with a gradual appreciation of the renminbi while continuing to manage the pace of gains.
USD/CNY traded around 6.77 during the session, hovering near its lowest levels in several months as investors balanced China’s policy signals against expectations for US monetary policy.
Why Is USD/CNY Falling? The latest decline followed another stronger daily reference rate from the People’s Bank of China. The PBOC set the USD/CNY central parity rate at 6.7972, following Monday’s fixing of 6.7989, which marked the first official fixing below the 6.80 level since February 2023.
Although the latest fixing remained slightly weaker than market estimates, investors interpreted the move as another indication that Chinese authorities are becoming more comfortable with a firmer yuan after months of currency stability.
China allows the yuan to trade within a 2% band around the daily reference rate, making the fixing one of the most closely watched policy tools in global foreign exchange markets.
PBOC Continues to Support Liquidity Alongside the currency fixing, the central bank injected 224 billion yuan through seven-day reverse repurchase agreements while keeping the policy rate unchanged at 1.40%.
The liquidity injection helps maintain stable funding conditions across China’s banking system without signaling a broader shift in monetary policy.
The combination of steady liquidity support and a stronger currency fixing suggests policymakers are attempting to balance economic growth with currency stability as global financial markets remain volatile.
Chinese Yuan Strength Reflects Policy Confidence Recent policy actions suggest Beijing is allowing the yuan to strengthen gradually rather than aggressively defending a weaker exchange rate.
A stronger currency can help reduce imported inflation, improve investor confidence and support capital inflows into Chinese financial markets.
However, authorities also remain cautious about allowing excessive appreciation that could hurt exporters, particularly as global demand remains uneven.
That explains why the official fixing has strengthened only gradually instead of moving sharply below market expectations.
US Dollar Outlook Remains a Key Driver of USD/CNY The US dollar continues to influence the direction of USD/CNY. Investors are awaiting fresh US inflation data and additional comments from Federal Reserve officials for clues about the path of US interest rates.
If expectations for further Federal Reserve tightening increase, the dollar could recover and limit further yuan gains. Conversely, softer US economic data may place additional pressure on the greenback, allowing USD/CNY to continue moving lower.
USD/CNY Technical Outlook The broader trend suggests USD/CNY remains under moderate downside pressure after slipping below the important 6.80 psychological level. The Bloomberg chart shows the pair trading near 6.7705, down around 0.14% during the latest session, reflecting continued demand for the yuan.
Immediate support is located around 6.75, a level that has attracted buyers in recent sessions. A sustained move below this zone could expose the pair to fresh downside as yuan strength accelerates.
On the upside, 6.80 remains the first major resistance level. A recovery above that area could encourage a move toward 6.83, particularly if US dollar strength returns following upcoming inflation data or hawkish Federal Reserve commentary. For now, the technical picture points to range-bound trading, with policy signals from the PBOC and US macroeconomic data likely to determine the next directional move.
What Investors Are Watching Next Market participants will continue monitoring:
Upcoming US inflation data and Federal Reserve expectations. Future PBOC daily currency fixings for signs of further yuan support. Capital flows into Chinese financial markets. China’s economic data and policy announcements. Global risk sentiment and US-China trade developments. Any additional fixings below the 6.80 level could reinforce expectations that Chinese authorities are prepared to tolerate a stronger yuan, while stronger US economic data could slow the recent decline in USD/CNY.
Why is USD/CNY falling?
USD/CNY is declining because the Chinese yuan has strengthened after the People’s Bank of China set stronger daily reference rates, signaling support for gradual currency appreciation.
What is the PBOC fixing?
The PBOC fixing is the daily reference exchange rate set by China’s central bank. The yuan is allowed to trade within a 2% band around this official midpoint.
What are the key USD/CNY levels to watch?
Key support is around 6.75, while the first major resistance remains near 6.80, followed by 6.83.
Why does the PBOC manage the yuan?
The central bank uses the daily fixing to maintain currency stability, support economic growth, control inflation and prevent excessive volatility in foreign exchange markets.
PPL plánuje v letech 2026 až 2029 investovat zhruba 23 miliard USD, aby podpořila růst regulované báze aktiv o asi 10,3 % ročně. Akcie se obchodují na 17,74násobku forwardového zisku, nad průměrem odvětví.
Key Takeaways PPL plans to invest $23 billion from 2026 to 2029, supporting annual rate base growth of about 10.3%.Data center demand has climbed to 28.3 GW in Pennsylvania, while Kentucky's pipeline reached 12.9 GW.PPL trades at 17.74X forward earnings, while its trailing ROE of 9.41% remains below the industry average. PPL Corporation’s (PPL - Free Report) shares are trading at a premium to the Zacks Utility -Electric Power industry. Its 12-month forward price-to-earnings of 17.74X is higher than the industry average of 15.6X and the broader Zacks Utility sector’s 15.45X.
PPL Corporation is well-positioned to capitalize on increasing electricity demand from data centers, particularly in Pennsylvania and Kentucky, where the rapid expansion of these energy-intensive facilities is driving long-term load growth.
However, PPL faces rising competition in the transmission business, which could pressure operations, while unforeseen operational disruptions may adversely affect its financial performance.
PPL Trading at a Premium Valuation
Image Source: Zacks Investment Research
Other operators in this space, Duke Energy (DUK - Free Report) and Ameren Corporation (AEE - Free Report) , are trading at P/EF12M of 18.28 and 20.3, respectively, a premium to the industry.
PPL’s shares have lost 8.4% in the past three months, wider than the Zacks Utility-Electric Power industry’s decrease of 1.5%.
Price Performance (Three Months)
Image Source: Zacks Investment Research
Despite trading at a premium valuation, PPL Corporation's recent share price weakness may have investors wondering whether now is an opportune time to buy. Let’s explore the key factors that will help determine if the stock merits consideration at current levels.
Factors Supporting PPL’s Earnings GrowthPPL continues to benefit from economic expansion and robust data center demand across its service territories. In Pennsylvania, advanced-stage data center demand has increased to nearly 28.3 gigawatts (“GW”) from 25.2 GW, while Kentucky's economic development pipeline now indicates potential load growth of 12.9 GW through 2032, up from the earlier estimate of 8.5 GW.
To capitalize on these opportunities, PPL plans to invest approximately $23 billion between 2026 and 2029, supporting an average annual rate base growth of about 10.3% through 2029. The company's investments in generation, transmission and distribution infrastructure, coupled with ongoing grid modernization initiatives, are enhancing system reliability and reducing customer outages.
A key advantage is that more than 60% of PPL's capital investment program qualifies for contemporaneous recovery, mitigating the effects of regulatory lag on earnings. This framework enables the company to recover capital investments more quickly, strengthening cash flows and supporting the timely execution of its long-term growth strategy.
Additionally, it remains committed to disciplined cost management, creating value for both the company and customers. Since 2021, PPL has reduced total operating expenses by $170 million as of 2025. Continued focus on cost-control initiatives is expected to support margin expansion, improve profitability and reinforce the company's long-term financial performance.
Headwinds for PPL StockPPL continues to encounter competition in Pennsylvania's transmission market. Moreover, adverse weather conditions, cybersecurity incidents, equipment outages and fuel supply interruptions could disrupt operations and pressure the company's earnings and profitability.
PPL Stock’s Earnings Estimate Moving UpPPL expects 2026 earnings to be in the range of $1.90-$1.98 per share. The Zacks Consensus Estimate for PPL’s 2026 and 2027 earnings per share indicates year-over-year growth of 7.73% and 8.06%, respectively.
Image Source: Zacks Investment Research
The same for DUK’s 2026 and 2027 earnings per share indicates year-over-year growth of 6.34% and 6.41%, respectively.
PPL Raises Shareholders' ValuePPL has a long history of returning value to shareholders through regular dividend payments and expects to increase its annual dividend by 4-6% over the long term, subject to board approval. The company currently pays a quarterly dividend of 28.5 cents per share, translating to an annualized dividend of $1.14. With a dividend yield of 3.19%, PPL offers a more attractive income stream than the S&P 500's average yield of 1.35%.
PPL has raised dividends for its shareholders four times in the past five years. Check PPL’s dividend history here.
Ameren also distributes dividends to its shareholders. The current annual dividend rate of Ameren is $3 per share, reflecting a dividend yield of 2.66%.
PPL’s Return Is Lower Than the IndustryReturn on equity (“ROE”) is a financial ratio that measures how well a company uses its shareholders’ equity to generate profits. The current ROE of the company indicates that it is using shareholders’ funds more efficiently than peers.
PPL’s trailing 12-month ROE is 9.41%, lower than the industry average of 11.21%.
Image Source: Zacks Investment Research
PPL’s Debt to CapitalUtility operations are capital-intensive and companies in this sector often need to borrow to fund long-term projects when internal resources are insufficient. The company is also borrowing funds to meet its capital requirements.
PPL’s current debt to capital is 55.88% compared with its industry average of 52.69%. This shows the company is utilizing lower debts than peers to run its operations.
Image Source: Zacks Investment Research
Summing UpPPL is benefiting from accelerating data center-driven electricity demand and timely rate recovery mechanisms, which enable it to efficiently finance the long-term growth initiatives. The company is also enhancing grid reliability through significant investments in infrastructure, IT modernization and an expanded $23 billion capital investment plan, positioning it to meet rising electricity demand across the service territories.
However, PPL is currently trading at a premium valuation, generates returns below the industry average and carries a higher debt burden than many of its peers. Given these factors, existing investors may continue holding this Zacks Rank #3 (Hold) stock, while prospective investors should wait for a more attractive entry point before initiating a position in PPL.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Indiana American Water zahajuje stavbu nového vodojemu s kapacitou 1,5 milionu galonů v Noblesville v rámci investice 15 milionů USD do rozšíření a modernizace sítě. Projekt má zvýšit kapacitu, spolehlivost i tlak vody.
, /PRNewswire/ -- Indiana American Water today announced construction of a new 1.5‑million‑gallon elevated water tank in the Innovation Mile in eastern portion of the City Noblesville, supporting the rapidly expanding area surrounding Hamilton Town Center. The project is part of a larger $15 million system investment that includes additional water storage, two booster-station upgrades, and three phases of new water mains—further demonstrating the company's commitment to strengthening water infrastructure and helping ensure reliable service for homes and businesses across the Noblesville distribution system.
Located on Olio Road near Noblesville Fire Station No. 77, the nearly 150‑foot‑tall structure features a concrete pedestal and steel tank designed to serve the region's long-term growth. Recently built, the tank proudly displays the Noblesville city brand on south side and Indiana American Water's logo on the other.
The combined tank, booster station, and water main improvements will increase storage capacity, enhance system reliability, improve water pressure, and bolster fire protection throughout the community.
"Adding a water tank near Noblesville's 600-acre innovation, tech, sports and entertainment district supports the continued growth of Noblesville's east side," said Noblesville Mayor Chris Jensen. "The City of Noblesville is grateful to Indiana American Water for its partnership in providing reliable service that helps sustain ongoing economic development and quality of life for residents."
Indiana American Water engineering project manager, Ryan Bane, said, "This project reflects our ability to strategically plan for growth while working hand in hand with the City of Noblesville to meet the community's long‑term needs. By increasing storage capacity and strengthening our system, we're supporting continued economic development in this rapidly expanding area."
Construction of the elevated water tank and associated system improvements is expected to be completed and operational by early Oct. 2026. Indiana American Water recognizes and appreciates the strong support and collaboration of the City of Noblesville, Hamilton County, and the project team—including- Caldwell Tanks, Inc., Tank Industry Consultants, Culy Contracting, F.A. Wilhelm Construction, American Structurepoint, GFT Infrastructure, and Aqualign Engineering.
This project is funded through customer rates from across the state and reflects Indiana American Water's ongoing commitment to investing in the local infrastructure that keeps water service reliable, safe, and ready to meet future needs.
About American Water
American Water (NYSE: AWK) is the largest regulated water and wastewater utility company in the United States. With a history dating back to 1886, We Keep Life Flowing® by providing safe, clean, reliable and affordable drinking water and wastewater services to more than 14 million people with regulated operations in 14 states and on 18 military installations. American Water's 6,500 talented professionals leverage their significant expertise and the company's national size and scale to achieve excellent outcomes for the benefit of customers, employees, investors and other stakeholders.
For more information, visit amwater.com and join American Water on LinkedIn, Facebook, X and Instagram.
About Indiana American Water
Indiana American Water, a subsidiary of American Water is the largest regulated water utility in the state, providing high-quality and reliable water and wastewater services to approximately 1.5 million people. For more information, visit amwater.com/inaw and join Indiana American Water on LinkedIn, Facebook, X and Instagram.
Atlantic Union čeká za čtvrtletí pokles zisku na akcii na 0,92 USD a tržeb na 394,98 mil. USD. Konsensus počítá s meziročním poklesem zisku o 3,2 % a tržeb o 3 %.
The market expects Atlantic Union (AUB - Free Report) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended June 2026. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.
The earnings report, which is expected to be released on July 21, might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower.
While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise.
Zacks Consensus EstimateThis holding company for Atlantic Union Bank is expected to post quarterly earnings of $0.92 per share in its upcoming report, which represents a year-over-year change of -3.2%.
Revenues are expected to be $394.98 million, down 3% from the year-ago quarter.
Estimate Revisions TrendThe consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.
Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change.
Price, Consensus and EPS Surprise
Earnings WhisperEstimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. Our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction) -- has this insight at its core.
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.
A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.
Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).
How Have the Numbers Shaped Up for Atlantic Union?For Atlantic Union, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. This has resulted in an Earnings ESP of -0.81%.
On the other hand, the stock currently carries a Zacks Rank of #3.
So, this combination makes it difficult to conclusively predict that Atlantic Union will beat the consensus EPS estimate.
Does Earnings Surprise History Hold Any Clue?Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.
For the last reported quarter, it was expected that Atlantic Union would post earnings of $0.88 per share when it actually produced earnings of $0.89, delivering a surprise of +1.14%.
Over the last four quarters, the company has beaten consensus EPS estimates three times.
Bottom LineAn earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.
That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
Atlantic Union doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.
An Industry Player's Expected ResultsAnother stock from the Zacks Banks - Northeast industry, Independent Bank Corp. (INDB - Free Report) , is soon expected to post earnings of $1.77 per share for the quarter ended June 2026. This estimate indicates a year-over-year change of +41.6%. Revenues for the quarter are expected to be $257.73 million, up 41.8% from the year-ago quarter.
The consensus EPS estimate for Independent Bank Corp. has been revised 0.9% lower over the last 30 days to the current level. However, a higher Most Accurate Estimate has resulted in an Earnings ESP of +0.94%.
When combined with a Zacks Rank of #3 (Hold), this Earnings ESP indicates that Independent Bank Corp. will most likely beat the consensus EPS estimate. Over the last four quarters, the company surpassed consensus EPS estimates three times.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
Western Alliance za čtvrtletí očekává zisk 2,33 USD na akcii, což je meziročně o 12,6 % více, a tržby 973,85 mil. USD, tedy o 13,8 % více. Odhad EPS byl za posledních 30 dní snížen o 3,16 %.
The market expects Western Alliance (WAL - Free Report) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2026. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.
The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on July 21. On the other hand, if they miss, the stock may move lower.
While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise.
Zacks Consensus EstimateThis bank holding company is expected to post quarterly earnings of $2.33 per share in its upcoming report, which represents a year-over-year change of +12.6%.
Revenues are expected to be $973.85 million, up 13.8% from the year-ago quarter.
Estimate Revisions TrendThe consensus EPS estimate for the quarter has been revised 3.16% lower over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.
Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change.
Price, Consensus and EPS Surprise
Earnings WhisperEstimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. Our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction) -- has this insight at its core.
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.
A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.
Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).
How Have the Numbers Shaped Up for Western Alliance?For Western Alliance, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. This has resulted in an Earnings ESP of -2.98%.
On the other hand, the stock currently carries a Zacks Rank of #4.
So, this combination makes it difficult to conclusively predict that Western Alliance will beat the consensus EPS estimate.
Does Earnings Surprise History Hold Any Clue?While calculating estimates for a company's future earnings, analysts often consider to what extent it has been able to match past consensus estimates. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.
For the last reported quarter, it was expected that Western Alliance would post earnings of $1.48 per share when it actually produced earnings of $2.22, delivering a surprise of +50.00%.
Over the last four quarters, the company has beaten consensus EPS estimates four times.
Bottom LineAn earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.
That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
Western Alliance doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.
Expected Results of an Industry PlayerAnother stock from the Zacks Banks - West industry, RBB (RBB - Free Report) , is soon expected to post earnings of $0.53 per share for the quarter ended June 2026. This estimate indicates a year-over-year change of +1.9%. Revenues for the quarter are expected to be $33.06 million, down 7.7% from the year-ago quarter.
The consensus EPS estimate for RBB has been revised 0.4% higher over the last 30 days to the current level. However, a lower Most Accurate Estimate has resulted in an Earnings ESP of -4.49%.
When combined with a Zacks Rank of #1 (Strong Buy), this Earnings ESP makes it difficult to conclusively predict that RBB will beat the consensus EPS estimate. The company beat consensus EPS estimates in each of the trailing four quarters.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
Truist Financial čeká za 2. čtvrtletí růst zisku na akcii o 18,7 % na 1,08 USD díky silné poptávce po úvěrech a vyšším poplatkovým výnosům. Tržby mají stoupnout o 4,5 % na 5,21 miliardy USD.
Key Takeaways Truist's Q2 earnings are expected to rise 18.7%, with sales projected to increase 4.5%.Strong loan demand and stable funding costs are expected to lift TFC's NII 1.3% y-o-y to $3.63 billion.Fee income is projected to grow, while expenses and non-performing assets are expected to rise. Truist Financial (TFC - Free Report) is scheduled to report second-quarter 2026 results on July 17 before the opening bell. The overall impressive lending scenario in the quarter is likely to have supported the company’s net interest income (NII).
Per the Fed’s latest data, the demand for commercial and industrial (C&I) loans (accounting for almost 50% of TFC’s total loans and leases held for investment) was robust in the to-be-reported quarter. Demand for consumer loans (almost 40% of total loans) was solid.
The Zacks Consensus Estimate for TFC’s average earning assets for the quarter is pegged at $488.4 billion, indicating a 1.5% rise from the prior-year quarter.
In the second quarter, the Federal Reserve kept interest rates unchanged and signaled a hike later in the year. This, along with strong loan demand, decent economic growth and stabilizing funding/deposit costs, is expected to have driven Truist’s net interest income (NII) higher. The consensus estimate for NII is pegged at $3.63 billion, implying a 1.3% increase.
Management anticipates NII to increase approximately 1% sequentially, primarily driven by one additional day and increased client deposit balances.
Other Factors to Impact Truist’s Q2 EarningsNon-Interest Income: Though mortgage rates increased in the second quarter to the mid-6% range, they were lower than the prior-year quarter level. Hence, refinancing activities and origination volume were decent. Thus, Truist’s mortgage banking income is expected to have risen. The Zacks Consensus Estimate for the metric of $121.2 million indicates a 23.6% jump from the prior-year quarter.
Higher client activity and volatility in the capital markets, along with industry-wide decent deal-making activities, in the to-be-reported quarter are expected to have supported TFC’s corresponding fee income. The consensus estimate for investment banking and trading income of $336.7 million indicates a year-over-year jump of 64.2%.
The strong lending backdrop is likely to have supported Truist’s lending-related fees. The Zacks Consensus Estimate for the same is $100.2 million, indicating a rise of 1.2%. As the U.S. markets witnessed investor rotation amid the changing macro environment, there has been a rise in asset inflows. The consensus estimate for wealth management income of $375.6 million suggests an increase of 7.9%.
The Zacks Consensus Estimate for total non-interest income is pegged at $1.56 billion, which indicates an 11.6% rise from the prior-year quarter.
Management expects non-interest income to decline almost 1% sequentially due to Investment Banking and Trading income, partially offset by higher other income and card and treasury management fees.
Expenses: Truist has been witnessing a continued rise in overall non-interest expenses over the past several quarters because of investments in technology, inflationary pressure and expansion efforts. A similar trend is expected to have continued in the second quarter.
Management expects GAAP non-interest expenses to rise 3-4% from $3 billion in the first quarter of 2026. This will be due to higher personal costs.
Asset Quality: Truist is unlikely to have set aside a substantial amount for potential loan delinquencies, given the modest improvement in the operating environment, supported by resilient economic growth, broadly stable credit conditions and the announced ceasefire in the Middle East. However, robust lending and persistently higher inflation are likely to have weighed on provision numbers.
The Zacks Consensus Estimate for total non-accrual loans and leases of $2.16 billion suggests a 71.4% year-over-year jump. The consensus estimate for total non-performing assets is $2.23 billion, indicating a 69.5% surge.
Truist’s Q2 Earnings & Sales ExpectationsThe Zacks Consensus Estimate for TFC’s earnings of $1.08 per share has remained unchanged over the past seven days. This indicates growth of 18.7% from the year-ago reported number.
The consensus estimate for sales is pegged at $5.21 billion, suggesting a 4.5% rise. The company expects revenues to remain relatively stable at $5.2 billion sequentially.
What the Zacks Model Unveils for TFCAccording to our quantitative model, the chances of Truist beating the Zacks Consensus Estimate for earnings this time are high. This is because it has the right combination of the two key ingredients — a positive Earnings ESP and a Zacks Rank #3 (Hold) or better.
You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Earnings ESP: The Earnings ESP for Truist is +0.23%.
Zacks Rank: TFC currently carries a Zacks Rank #3.
TFC’s Peers Worth ConsideringHere are a couple of Truist’s peer bank stocks that you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this time:
U.S. Bancorp (USB - Free Report) is scheduled to announce second-quarter 2026 results on July 16. The company carries a Zacks Rank #2 (Buy) and has an Earnings ESP of +0.34% at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Quarterly earnings estimates for U.S. Bancorp have been revised upward to $1.28 over the past week.
The Earnings ESP for M&T Bank (MTB - Free Report) is +0.13%, and it carries a Zacks Rank #2. The company is slated to report second-quarter 2026 numbers tomorrow.
Over the past seven days, the Zacks Consensus Estimate for M&T Bank’s quarterly earnings has remained unchanged at $4.66.
Wall Street čeká, že Ally Financial oznámí za čtvrtletí zisk 1,27 USD na akcii, meziročně o 28,3 % více, při výnosech 2,23 miliardy USD. Firma reportuje 21. července.
Wall Street expects a year-over-year increase in earnings on higher revenues when Ally Financial (ALLY - Free Report) reports results for the quarter ended June 2026. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.
The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on July 21. On the other hand, if they miss, the stock may move lower.
While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on the earnings call, it's worth handicapping the probability of a positive EPS surprise.
Zacks Consensus EstimateThis auto finance company and bank is expected to post quarterly earnings of $1.27 per share in its upcoming report, which represents a year-over-year change of +28.3%.
Revenues are expected to be $2.23 billion, up 6.9% from the year-ago quarter.
Estimate Revisions TrendThe consensus EPS estimate for the quarter has been revised 0.55% higher over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.
Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts.
Price, Consensus and EPS Surprise
Earnings WhisperEstimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. Our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction) -- has this insight at its core.
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.
A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.
Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).
How Have the Numbers Shaped Up for Ally Financial?For Ally Financial, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. This has resulted in an Earnings ESP of -2.41%.
On the other hand, the stock currently carries a Zacks Rank of #3.
So, this combination makes it difficult to conclusively predict that Ally Financial will beat the consensus EPS estimate.
Does Earnings Surprise History Hold Any Clue?Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.
For the last reported quarter, it was expected that Ally Financial would post earnings of $0.93 per share when it actually produced earnings of $1.11, delivering a surprise of +19.35%.
Over the last four quarters, the company has beaten consensus EPS estimates four times.
Bottom LineAn earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.
That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
Ally Financial doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
Wendy’s dál tlačí Project Fresh, který má zlepšit menu, provoz i spokojenost zákazníků a postupně podpořit marže. Ve 1. čtvrtletí ale provozní marže v USA klesla na 11,4 %.
Key Takeaways Wendy's is using Project Fresh to enhance menu quality, operations and customer satisfaction.WEN is growing digital sales with AI-powered recommendations and expanding its international footprint.Management expects improving execution and easing cost pressures to support margin recovery. The Wendy's Company (WEN - Free Report) continues to face margin headwinds, but management believes its comprehensive turnaround strategy, dubbed Project Fresh, could gradually improve profitability as the year unfolds. While first-quarter performance remained under pressure, executives pointed to encouraging operational improvements that could support both sales and margins over time.
During the quarter, U.S. company-operated restaurant margin fell to 11.4%, reflecting softer customer traffic, elevated beef costs, investments in food quality upgrades and labor inflation. Adjusted EBITDA also declined as the company stepped up spending on marketing, field support and international expansion. Despite these challenges, Wendy’s maintained its full-year outlook, signaling confidence that conditions will improve in the second half.
Project Fresh is central to that recovery. Wendy’s is upgrading the core menu with improved hamburger buns, enhanced condiments and a revamped spicy chicken sandwich while strengthening value offerings through its Biggie Deals platform. At the same time, WEN is focusing on cleaner restaurants, better order accuracy and enhanced employee training, areas where company-operated restaurants have already outperformed the broader system. Management believes stronger execution will increase customer satisfaction, encourage repeat visits and ultimately lift restaurant economics.
Digital initiatives are also contributing to the turnaround. U.S. digital sales increased, supported by AI-powered recommendations in the mobile app and continued investments in the digital ordering experience. Meanwhile, Wendy’s is expanding internationally, highlighted by a franchise agreement to develop up to 1,000 restaurants in China, providing an additional long-term growth avenue.
Although commodity inflation, especially beef costs and cautious consumer spending remain near-term risks, Wendy’s expects improving sales trends, better operational execution and easing cost pressures later in the year to support margin recovery. If Project Fresh continues to gain traction, the company could gradually rebuild profitability while laying the foundation for sustainable long-term growth.
Peers Are Also Balancing Costs With Operational ImprovementsWendy's turnaround efforts mirror broader trends across the quick-service restaurant industry, where operators are working to protect margins while navigating inflation and cautious consumer spending. McDonald's (MCD - Free Report) continues to focus on affordability through value offerings while leveraging its vast digital ecosystem, loyalty program and operational efficiencies to offset higher labor and commodity costs. Its scale and strong franchise network have helped McDonald's preserve profitability despite a challenging demand environment.
Restaurant Brands International (QSR - Free Report) , the parent of Burger King, is pursuing a similar strategy through its "Reclaim the Flame" initiative. The company is investing in restaurant modernization, improved operations and targeted marketing to strengthen guest traffic and franchisee economics. Menu innovation and digital expansion also remain as Restaurant Brands International's key priorities for driving profitable growth.
Compared with these rivals, Wendy's differentiates itself through Project Fresh, which combines menu quality upgrades, operational improvements and system optimization. While margin pressure remains in the near term, the successful execution of these initiatives could help Wendy's narrow the profitability gap with larger competitors over time.
WEN’s Price Performance, Valuation & EstimatesShares of Wendy’s have dropped 31.6% in the past year compared with the industry’s 6.5% decline.
Price Performance
Image Source: Zacks Investment Research
From a valuation standpoint, WEN trades at a forward price-to-sales (P/S) multiple of 0.64, below the industry’s average of 3.37.
WEN’s P/S Ratio (Forward 12-Month) vs. Industry
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for WEN’s 2026 earnings per share (EPS) implies a year-over-year decline of 34.1%. The EPS estimates for 2026 have remained unchanged in the past 30 days.
EPS Trend of WEN Stock
Image Source: Zacks Investment Research
WEN’s Zacks RankWEN stock currently carries a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Key Takeaways AMKR trades at 2.06X forward P/S versus the industry's 9.33X despite strong share gains and growth drivers.AMKR expects advanced packaging revenues to roughly triple in 2026 as AI demand lifts computing growth.Amkor Technology is expanding in Arizona to boost U.S. advanced packaging with 2028 production targeted. Amkor Technology (AMKR - Free Report) trades at a forward 12-month Price/Sales (P/S) multiple of 2.06X compared with the Zacks Electronics-Semiconductors industry average of 9.33X and the Zacks Computer & Technology sector average of 6.98X. The valuation remains cheap despite AMKR's long-term growth opportunity being supported by rising demand for advanced packaging solutions from customers, such as Apple (AAPL - Free Report) and Advanced Micro Devices (AMD - Free Report) .
AMKR’s P/S Valuation
Image Source: Zacks Investment Research
AMKR shares have climbed 67.3% year to date, well ahead of the industry's 50.3% return and the sector's 17% advance. The rally reflects rising demand for advanced packaging, fueled by increasing AI and high-performance computing investments from companies like NVIDIA (NVDA - Free Report) , alongside steady demand across the premium smartphone and automotive markets.
AMKR’s YTD Price Performance
Image Source: Zacks Investment Research
Advanced Packaging Demand Remains a Structural TailwindAMKR's growth engine remains its expanding footprint in advanced packaging, where chiplet-based architectures and high bandwidth memory integration push packaging decisions earlier into system design. AMKR remains one of the few suppliers able to execute at this level of complexity and scale across flip chip, 2.5D and High Density Fan Out (HDFO) platforms. Its HDFO bridge program with Advanced Micro Devices is expected to ramp up in 2027, while NVIDIA has validated AMKR's ability to turn complex silicon into deployable systems at volume. The HDFO platform now spans over five customers at various qualification stages, expanding AMKR's data center pipeline well beyond a single program.
This shift reflects the broader move from transistor scaling toward package-level integration for performance gains, and constrained global advanced packaging capacity supports a favorable long-term demand backdrop for AMKR.
Computing revenues rose 19% year over year in the first quarter of 2026, with AI data center strength offsetting soft personal computer demand. For the second quarter, computing revenues are expected to grow in the mid-single digits sequentially on the new data center CPU ramp, while full-year advanced packaging revenues are projected to roughly triple in 2026.
The Zacks Consensus Estimate for AMKR's 2026 earnings is pegged at $2.08 per share, indicating growth of 38.67% year over year.
Arizona Buildout Expands Addressable OpportunityAmkor Technology's $7 billion two-phase Arizona campus is set to complete the domestic advanced packaging and test flow that leading-edge wafer fabrication in the United States currently lacks. Phase 1 is on track for high-volume manufacturing beginning in 2028, backed by roughly $2.8 billion in combined government incentives, tax credits and customer co-investments. As utilization builds toward full-scale, management expects gross margin at the facility to exceed 30%, well ahead of AMKR's corporate average, with breakeven anticipated around 2029. The Advanced Micro Devices program is expected to be among the first to onshore into Arizona once qualified, giving AMKR an early foothold in domestic compute demand well ahead of full-scale production. AMKR has also secured an additional 67 acres of adjacent land, giving the company room to expand further as a potential second phase takes shape.
Smartphone and Automotive Markets Broaden AMKR’s Growth BaseAMKR's growth story extends well beyond AI and data center programs. Communications remains AMKR's largest end market, climbing 42% from a year earlier on strong premium-tier smartphone demand tied to Apple's current-generation product cycle, with continued strength expected to drive mid- to high-single-digit sequential growth in the second quarter.
Automotive and industrial revenues climbed 28% year over year in the same period, supported by rising content per vehicle as ADAS, in-car computing and electrification adoption expand and are guided to grow further in the mid-single digits sequentially. This diversification strengthens AMKR's overall positioning, complementing its expanding data center relationships with customers such as NVIDIA and giving the company multiple avenues to sustain double-digit growth across a broadening set of end markets.
ConclusionAMKR's long-term growth story remains firmly intact. Rising adoption of advanced packaging across AI and high-performance computing, expanding engagements with leading chipmakers and resilient premium smartphone demand driven by Apple provide multiple growth catalysts. Combined with the Arizona expansion and an attractive valuation relative to the industry, these factors position AMKR to deliver sustained earnings growth over the long term.
AMKR currently carries a Zacks Rank #2 (Buy). This implies that investors should start accumulating the stock at current levels. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Quanta těží z rostoucích investic utilit do přenosových sítí a uzavírá víceleté dohody na infrastrukturních programech. Na konci 1. čtvrtletí měla rekordní backlog 48,5 mld. USD, z toho 12měsíční 28,2 mld. USD, meziročně o 45,4 %.
Key Takeaways Quanta is benefiting as utilities expand transmission networks and increase long-term capital spending.PWR is working with utilities on multiyear capital planning and integrated infrastructure solutions.Quanta ended Q1 with a record $48.5B backlog, including a 12-month backlog of $28.2B, up 45.4%. Quanta Services, Inc. (PWR - Free Report) is well positioned to benefit from rising utility infrastructure spending as power companies expand their networks to support growing electricity demand. Utilities are increasing long-term capital investments as transmission systems grow in scale and technology-driven power demand accelerates, creating favorable conditions for infrastructure providers with broad execution capabilities. This environment aligns well with Quanta's integrated business model and expanding role in large utility infrastructure programs.
Quanta has strengthened its position by becoming more deeply involved in customers' long-term capital planning rather than participating only at the project bidding stage. The company is increasingly working alongside utilities as they develop multiyear capital programs, allowing it to provide integrated engineering, procurement, construction and supply-chain solutions across large and complex infrastructure projects. This approach also supports greater execution certainty, helping customers manage labor availability, project schedules and supply-chain challenges more effectively.
The company's expanding role in utility infrastructure programs is also improving long-term project visibility. Management indicated that customer relationships have evolved into broader strategic partnerships, with a growing share of work being negotiated directly as infrastructure programs become larger and more complex. Quanta ended the first quarter with a record backlog of $48.5 billion, up from $35.3 billion a year ago, including a 12-month backlog of $28.2 billion, up 45.4%, reinforcing strong multiyear revenue visibility.
As utilities continue investing in transmission networks and broader capital programs, Quanta's integrated service offering, long-standing customer relationships and growing participation in multiyear infrastructure planning position it to benefit from sustained utility infrastructure spending.
How Does Quanta Compare With Infrastructure Peers?Quanta has established a leading position in North America's power infrastructure market, benefiting from growing investments in grid modernization, transmission expansion and electrification. As investors assess whether the company can sustain the long-term growth, comparisons with EMCOR Group, Inc. (EME - Free Report) and MasTec, Inc. (MTZ - Free Report) highlight its differentiated exposure to the evolving utility infrastructure landscape.
EMCOR is also benefiting from robust demand across electrical and mechanical construction, supported by data centers, manufacturing, health care and institutional projects. The company ended the first quarter with remaining performance obligations of $15.62 billion, reflecting strong project visibility. However, EMCOR’s growth remains more closely tied to building construction and facility-related services than utility transmission infrastructure.
MasTec is a closer peer, with exposure to power delivery, telecom, clean energy, pipeline and data center infrastructure. The company reported a record backlog of $20.3 billion and continues to benefit from investments in grid reliability, transmission expansion and AI-driven electricity demand. However, Quanta's integrated solutions platform, manufacturing investments and strong backlog position it to capture a broader share of North America's multiyear grid modernization opportunity.
PWR’s Price Performance, Valuation & EstimatesPWR stock has rallied 53.2% in the year-to-date (“YTD”) period, outperforming the Zacks Engineering - R and D Services industry, the broader Construction sector and the S&P 500 index.
PWR YTD Share Price Performance
Image Source: Zacks Investment Research
From a valuation standpoint, PWR trades at a forward 12-month price-to-earnings ratio of 42.16X, well above the industry’s 28.47X, as shown below.
PWR Valuation
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Quanta’s 2026 earnings per share has remained unchanged at $14.03 in the past 30 days. This indicates expected earnings growth of 30.5% year over year.
Image Source: Zacks Investment Research
PWR’s Zacks RankQuanta currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
AeroVironment čelí hromadné investorské žalobě kvůli údajným zavádějícím tvrzením kolem programu SCAR a jeho vyhlídek. Firma po stop-work order a zrušení kontraktu vykázala ve 3. fiskálním čtvrtletí provozní ztrátu 179,0 mil. USD.
LOS ANGELES, July 14, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises AeroVironment, Inc., (“AeroVironment” or the "Company") (NASDAQ: AVAV) investors of a class action on behalf of investors that bought securities between June 25, 2025 and March 10, 2026, inclusive (the “Class Period”). AeroVironment investors have until July 27, 2026 to file a lead plaintiff motion.
Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: [email protected], to discuss their legal rights, or join the case via https://portnoylaw.com/aerovironment-inc. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
AeroVironment designs, develops, produces, delivers, and supports a portfolio of robotic systems and related services for government agencies and businesses. The AeroVironment class action lawsuit alleges on May 1, 2025, AeroVironment announced it had completed the acquisition of BlueHalo, LLC, which had previously been awarded a contract to support the U.S. Space Force’s Satellite Communication Augmentation Resource (“SCAR”) program. The SCAR program represents the U.S. Space Force’s efforts to modernize antennas used by the Satellite Control Network (“SCN”), which is comprised of 19 fixed antennas across the world and executes tasks such as tracking satellites, transmitting signals, and conducting telemetry, or accessing data from satellites to assess their status and health, according to the complaint.
The AeroVironment class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) AeroVironment understated the likelihood that it would imminently face competition from other vendors for the work it performed in connection with the SCAR program and the U.S. Space Force’s ongoing efforts to modernize the SCN; and (ii) accordingly, defendants overstated AeroVironment’s business and financial prospects.
The AeroVironment class action lawsuit further alleges that on January 20, 2026, AeroVironment announced that the U.S. government had issued a stop work order on AeroVironment’s agreement to deliver BADGER systems to the SCAR program. In the same announcement, AeroVironment allegedly stated that the stop work order “allows for the parties to negotiate an amended agreement for the future of the SCAR program” and that “[t]he Company expects to continue to deliver capabilities and products for the SCAR program.” On this news, the price of AeroVironment stock fell nearly 16%, according to the complaint.
Then, on March 2, 2026, SpaceNews allegedly reported that the U.S. Space Force was reopening the SCAR program and “reassessing how to move forward.” Space News quoted Colonel Owen Stevens, director of contracting at the Space Rapid Capabilities Office, which supervised SCAR, as stating: “We have been in conversations with the SAE [senior acquisition executive] for a little while now, and we are going to move into a new acquisition strategy for SCAR,” the complaint alleges. On this news, the price of AeroVironment stock fell more than 17%, according to the complaint.
Finally, on March 10, 2026, the complaint alleges that AeroVironment announced its financial results for the third quarter of fiscal year 2026. Among other items, AeroVironment allegedly reported a third-quarter operating loss of $179.0 million, compared to an operating loss of $3.1 million for the same period in fiscal year 2025. These financial results reflected the impact of a $151.3 million goodwill impairment in AeroVironment’s space division after the stop work order on AeroVironment’s BADGER systems built for the SCAR program, according to the AeroVironment class action lawsuit. AeroVironment also allegedly reported that the U.S. Space Force had terminated AeroVironment’s contract concerning the SCAR program, and as a result, it would have to “recompete” for the SCAR program. On this news, the price of AeroVironment stock fell more than 6%, the complaint alleges.
The Portnoy Law Firm represents investors in pursuing claims caused by corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.
Lesley F. Portnoy, Esq.
Admitted CA, NY and TX Bar [email protected]
310-692-8883
www.portnoylaw.com
Injective spustil Injective AI Agent SDK, který dává vývojářům jeden balík pro tvorbu on-chain AI agentů s přístupem k dokumentaci, příkazům i exekuci. SDK míří na finanční agenty, kteří mají na Injective pracovat s daty, peněženkami a transakcemi.
Injective is spearheading a new area for agentic finance to thrive.
Today we are introducing the Injective AI Agent SDK to give builders one package with the tools needed to create novel agents onchain. It connects documentation, chain commands, agent skills, and onchain execution in one setup.
AI development has changed. Builders direct agents. They give context. They set the goal. Then the agent reads, writes, checks, and executes.
However, financial agents need more than generic coding help. They need market data, transaction flows, current docs, balances, markets, bridges, wallets, and chain state.
Injective gives agents those rails with seamless accessibility for developers everywhere.
npm install -g @injectivelabs/ainj
One Install for the Injective AI StackThe SDK brings together the pieces developers usually assemble by hand.
Injective CLI
The injectived command gives agents direct access to core chain functions. Agents can query state, manage wallet flows, prepare transactions, and interact with Injective from the same command line interface used across the network.
Injective agent skills
Agent skills teach AI coding tools how Injective workflows actually work. The agent gets chain specific context across docs, commands, and examples.
Injective documentation MCP server
The documentation server connects agents to Injective source material while they build. That keeps answers grounded in the current developer stack.
Injective main MCP server
The main server gives agents a path to query, transact, and trade across Injective Mainnet and Testnet.
The result is simple. Builders spend less time wiring tools together and more time building the actual application.
Why AI Agents Need Purpose-Built Financial RailsAgents act constantly.
They check state. They compare markets. They rebalance portfolios. They test logic. They prepare transactions. They retry when conditions change.
That behavior breaks on expensive, slow infrastructure. It works on Injective.
Injective supports 650 millisecond block times, instant finality, and standard transaction fees around $0.0003. It also gives agents native financial modules, an onchain orderbook, and cross chain connectivity.
That performance gives agents room to operate. A trading agent can research a market and place an order inside the Injective environment. A treasury agent can read balances, inspect routes, and prepare actions onchain. A builder can ask for an application and give the agent the context to build against live Injective rails.
This is the chain doing what agents need.
From Prompt to Onchain ActionThe SDK is designed around the way developers already work with modern AI environments such as Claude Code, Cursor, Codex, and other MCP compatible tools.
With the SDK installed, an agent can do the following.
Search the Injective docs for the right workflow.Query wallet balances and market data.Prepare and sign Injective transactions.Open and close perpetual futures positions.Bridge assets across supported networks.Write EVM or Injective native applications with chain specific context.Reason about staking, token metadata, and onchain activity.The point is simple. Injective should be available wherever builders already direct agents to work.
Part of the Larger Injective RoadmapThe SDK fits directly into the Injective roadmap.
The Injective MCP Server brought natural language execution to perpetual futures. Injective agent skills made those workflows reusable. dAppBuilder lets users generate financial applications from prompts. The Injective Agents platform points toward autonomous agents with onchain identities and direct economic activity.
The SDK pulls that direction into a cleaner builder flow.
AI native finance needs a chain where agents can read, reason, and execute. Injective has the financial modules, settlement speed, and cross chain reach to make that real.
This reaches beyond trading. Agents can support stablecoin payments, real world asset workflows, treasury management, portfolio automation, institutional dashboards, and new financial applications that static interfaces struggle to handle.
Injective is turning finance into software agents can use.
What to Know Before You BuildThe SDK plugs into the AI development environments builders already use.
It works alongside tools such as Claude Code, Cursor, Codex, and MCP compatible agent setups. It gives those tools Injective context and execution paths.
User control stays at the center. Any action that writes to the chain still needs a funded wallet, signing approval, and thoughtful key management. Good agent design keeps keys local, exposes only the right context, and asks for approval before state changes.
Powerful agents need clear guardrails.
Get StartedThe Injective AI Agent SDK is live today.
npm install -g @injectivelabs/ainj
Read more in the Injective AI developer docs, explore the open source Injective agent skills, and follow Injective for what ships next.
About InjectiveInjective is a lightning fast interoperable layer one blockchain optimized for building premier Web3 finance applications. Injective provides developers with powerful plug-and-play modules for creating unmatched dApps. INJ is the native asset that powers Injective and its rapidly growing ecosystem. Injective is incubated by Binance and is backed by prominent investors such as Jump Crypto, Pantera and Mark Cuban.
Trane Technologies těží ze silné poptávky po komerčním HVAC; organické zakázky v 1. čtvrtletí 2026 meziročně vzrostly o 24 % a v Americe asi o 40 %.
Integrace Stellar Energy Americas přidala do backlogu téměř 1 miliardu USD.
Key Takeaways TT is benefiting from strong commercial HVAC demand and accelerating enterprise bookings growth.TT's Stellar Energy integration added nearly $1 billion to its backlog, boosting modular cooling leadership.TT continues returning capital through dividends and buybacks while maintaining strong liquidity. Shares of Trane Technologies plc (TT - Free Report) have had a decent run over the past three months. The stock has risen 3.8% compared with the industry's 6.6% growth. The Zacks S&P 500 composite rose 7.8% during the said time frame.
TT has a Growth Score of B. This style score condenses key financial metrics to reflect a fair sense of the quality and sustainability of its growth.
The company’s second-quarter 2026 earnings are expected to increase 9.5% year over year. Earnings for 2026 and 2027 are projected to rise 13.6% and 13.9% year over year, respectively. Revenues are expected to increase 9% in 2026 and 8.4% in 2027.
Factors That Bode Well for TTTrane Technologies benefits from robust demand for its customer-centric solutions, especially commercial HVAC. Rising global energy demand and the need for high-performance buildings support strong long-term growth for the company. TT is driving growth by catering to this demand with its energy-efficient HVAC systems, smart controls and sustainable climate solutions. TT reported that enterprise organic bookings growth was 24% year over year in the first quarter of 2026. Commercial HVAC bookings in the Americas rose approximately 40% year over year during the same period.
The company is also driving growth from rising data center demand as clients build out specialized cooling and infrastructure to power the rapid growth of artificial intelligence (AI) and cloud computing. During the latest quarterly earnings conference, management stated that the February 2026 integration of Stellar Energy Americas, Inc. boosted the backlog by nearly $1 billion and solidified Trane Technologies’ market leadership in the rapidly expanding modular cooling sector.
The company has demonstrated a strong commitment to its shareholders through consistent dividend payments and share repurchases, despite the fluctuations in its cash position. TT paid dividends of $683.7 million, $757.5 million and $837.3 million, while repurchasing shares worth $669.3 million, $1.3 billion and $1.5 billion in 2023, 2024 and 2025, respectively. This consistency underscores its dedication to creating long-term value for investors.
TT had a current ratio (a measure of liquidity) of 1.1 in the first quarter of 2026, which improved marginally from the preceding quarter's 1.09 due to an increase in cash reserves. A current ratio above 1 enables the company to pay off short-term obligations efficiently.
Key Risks to WatchTrane Technologies relies on its supply chain for essential commodities, mainly steel and non-ferrous metals. Thus, rising commodity prices, such as steel costs, can inflate expenses, squeeze profit margins and erode revenues and cash flow.
Global technology service providers operate in a fiercely competitive landscape. TT faces stiff competition in the HVAC market from firms such as Honeywell International, Siemens and Carrier. This competition fuels innovation across the industry while driving pricing pressures. Ongoing technology investments increase the challenge of maintaining profitability while competing for growth.
Trane Technologies currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Stocks to ConsiderA couple of better-ranked stocks in the Technology Services industry are Coherent Corp. (COHR - Free Report) and V2X, Inc. (VVX - Free Report) .
Coherent Corp. sports a Zacks Rank #1 at present. It has a long-term earnings growth expectation of 46.8%. COHR’s earnings beat estimates in three of the last four reported quarters and matched once, with an average surprise of 6.2%.
V2X, Inc. also flaunts a Zacks Rank of 1 at present. It has a long-term earnings growth expectation of 20.4%. VVX delivered a trailing four-quarter earnings surprise of 22.8%, on average.
F.N.B. Corporation zveřejní výsledky za 2. čtvrtletí po uzavření trhu ve čtvrtek 16. července. Analytici čekají zisk 42 centů na akcii a tržby 466,67 milionu USD.
F.N.B. Corporation (NYSE:FNB) will release its second quarter earnings report after the closing bell on Thursday, July 16.
Analysts expect the Pittsburgh, Pennsylvania-based company to report quarterly earnings of 42 cents per share, up from 36 cents per share in the year-ago period. The consensus estimate for FNB’s quarterly revenue is $466.67 million. It reported $438.21 million last year, according to Benzinga Pro.
On April 16, FNB posted in-line earnings for the first quarter.
Shares of FNB rose 0.5% to close at $18.93 on Monday.
Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let’s have a look at how Benzinga’s most-accurate analysts have rated the company in the recent period.
Considering buying FNB stock? Here’s what analysts think:
Photo via Shutterstock
Market News and Data brought to you by Benzinga APIs
FTI Consulting v 1. čtvrtletí zvýšila tržby o 9,5 % na 983,3 milionu USD a potvrdila celoroční výhled 3,94–4,10 miliardy USD. Firma zároveň držela 198 milionů USD v hotovosti, neměla krátkodobý dluh a vykázala current ratio 2,3.
Key Takeaways FTI Consulting's Q1'26 revenues rose 9.5%, reaffirming the guidance of $3.94-$4.10B.FCN ended Q1'26 with $198M in cash, no current debt and a 2.3 current ratio.FTI Consulting repurchased shares worth $126.8M in Q1'26, while cash flow and rising costs remain risks. FTI Consulting, Inc. (FCN - Free Report) shares have slipped 1.2% in the past year. While the shares have experienced a slight dip, the industry has plummeted 42.3%. The Zacks S&P 500 Composite has rallied 26.3% over the same period.
The Zacks Consensus Estimate for 2026 revenues is pegged at $4 billion. The figure is expected to increase 6.2% year over year. For 2027, the consensus estimate is pinned at $4.3 billion, suggesting a 7.3% rise from the preceding year’s actual.
For EPS, the consensus mark for 2026 is pegged at $9.1, indicating a 3.1% year-over-year rally. The Zacks Consensus Estimate for 2027 EPS is set at $11.29. The figure is expected to grow 24.1% from the preceding year’s actual.
Factors That Augur Well for FCN’s SuccessDiversification & International Operations Aid Top Line: FCN’s diversification mitigates the impacts of macroeconomic headwinds, crises, events and changes in a particular practice, industry, or country. In 2025, the company generated 37% of its revenues from international operations. The recent performance paints a growth picture, wherein FCN generated $983.3 million in revenues in the first quarter of 2026, up 9.5% year over year. Management is optimistic and banking on the growth trajectory, reaffirming its 2026 revenue guidance of $3.94-$4.10 billion.
Robust Liquidity Position: The company ended 2025 with a current ratio of 1.56, a figure that bodes well with investors as it highlights FCN’s ability to pay off short-term obligations with ease. The company held this performance as it recorded a current ratio of 2.3 during the first quarter of 2026, outpacing the industry average of 1.15. FCN’s liquidity relies on its strong balance sheet position that ended the first quarter of 2026 with a cash chest of $198 million against no current debt.
Image Source: Zacks Investment Research
Shareholder-Friendly Actions: In 2023, 2024 and 2025, the company repurchased shares worth $21 million, $10.2 million and $858.7 million, respectively. This initiative instills investor confidence. We expect investors to have been flattered by FCN repurchasing 787,098 shares during the first quarter of 2026 for $126.8 million. The company’s bottom line moved up to $1.9 from the year-ago quarter’s $1.74 despite lower net income, highlighting the success of its buyback strategy that supported per-share value.
Risks Faced by FTI ConsultingCash Flow Contraction: FCN experienced substantial turbulence in cash flow flexibility during 2025. The company ended 2025 with an operating cash flow of $152.1 million, down from the preceding year’s $395.1 million due to higher forgivable loan issuances, compensation and income tax payments. This drag in the operational cash flow led to a decline in the free cash flow to $93.6 million in 2025 from the preceding year’s $360.2 million.
On a similar note, the company reported a severe cash depletion during 2025, as evidenced by a 59.9% year-over-year drag in cash and cash equivalents.
Bottom-Line Shoulders Cost Pressure: During 2025, FCN experienced a 14.5% year-over-year jump in operating expenses, demonstrating an acceleration from a 7.7% year-over-year increase in 2024. This substantial rise has been primarily caused by $54.7 million year-over-year growth in direct costs of revenues and special charges of $25.3 million in 2025, exceeding growth of three times from the preceding year. This rising cost structure left an imprint on the company’s profitability, as net income declined by $9.2 million or 3.3%, year over year in 2025.
Nil Dividend: FCN has never declared a dividend and currently does not have any plan to pay out cash dividends on common stock. Therefore, the only way for investors to gain is price appreciation, which is not a guaranteed phenomenon. Hence, investors seeking income are expected to refrain from investing in this stock.
FCN’s Zacks Rank & Stocks to ConsiderThe company has a Zacks Rank #3 (Hold) at present.
Some better-ranked stocks from the broader Zacks Business Services sector are Coherent Corp. (COHR - Free Report) and Conduent (CNDT - Free Report) , currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Coherent Corp has a long-term earnings growth expectation of 46.8%. Coherent Corp delivered a trailing four-quarter earnings surprise of 6.2%, on average.
Conduent has a long-term earnings growth expectation of 8%. Conduent delivered a trailing four-quarter earnings surprise of 4%, on average.
EUR/USD po slabší americké CPI roste o více než 0,6 % v seanci a drží se nad 1,1400. Slabší inflace stlačila výnosy amerických dluhopisů i poptávku po dolaru. Meziroční CPI v USA vyšlo na 3,5 %.
As the trading week begins, the euro is once again showing a short-term bullish bias after the release of inflation data in the United States, which has helped ease strength around the U.S. dollar.
For now, EUR/USD is up more than 0.6% during the session and continues to trade above the 1.1400 level. This buying pressure is partly due to the fact that the new inflation data has triggered corrections in the U.S. bond market, a dynamic that does not favor the dollar.
If this behavior continues, relevant buying pressure could remain present in EUR/USD movements over the next few trading sessions.
U.S. CPI day arrives During the session, CPI data in the United States was released. Although an annual reading was expected, the official figure surprised to the downside and came in at 3.5%.
This figure marks an important change in the U.S. price dynamic, as it represents one of the most relevant declines of the year. In addition, June inflation moved away from the annual high of 4.2% and broke the upward trend that had been present in annual inflation levels since March.
With this result, inflation is once again moving somewhat closer to the central bank’s annual 2.00% target.
Source: TradingEconomics
This event is relevant for Federal Reserve expectations, as a consistent slowdown in inflation could prevent the view of a fully aggressive central bank from materializing over the coming months.
As inflation declines, the need to keep interest rates higher for a prolonged period also decreases. This perspective has started to be reflected in the 10-year U.S. bond market, where yields have shown some correction amid lower expectations of central bank aggressiveness.
After the upward trend seen last week, yields have started to move back below the 4.6% area, showing relevant weakness that had not been observed in recent sessions.
Source: TradingEconomics
The key point is that, as bond yields show weakness, the relative appeal of these fixed-income instruments compared to other markets may also decline. This could reduce the need to maintain consistent demand for dollars in order to access these types of assets.
This decline in bond yields coincides with weaker demand for U.S. dollars. This behavior is reflected in the DXY index, which measures the dollar’s strength against its main peers. The index is now showing a relevant decline and is approaching the 100-point reference area. This indicates that demand for dollars has started to weaken in the short term.
Source: TradingEconomics
With all of this in mind, the dynamic has been favorable for the euro. The release of the inflation data created renewed weakness in dollar demand, which could be allowing the euro to recover ground in the short term.
If the U.S. bond market fails to show attractive growth in yields, the dollar could continue to lose ground. In that scenario, EUR/USD could maintain relevant buying pressure over the next few trading sessions.
Technical outlook for EUR/USD
Source: StoneX, Tradingview
Recent recovery becomes relevant: Although a long bearish trend line has been present for months in average EUR/USD movements, the recent price recovery has started to weaken the long-term selling bias. This move could be opening room for a more neutral phase on the chart. Even though the bearish trend line has not yet been broken, price could start to stop forming new lows and enter a more consistent range. If this effect continues over the next few sessions and selling pressure fails to stabilize again, the continuation of the bearish trend line on the daily chart could start to come under pressure.
RSI: Now, the RSI has moved back toward the neutral 50 area. This suggests a balance between buying and selling impulses in the market. Rather than pointing to a clear directional move, the indicator highlights a possible phase of indecision that could remain relevant over the next few sessions.
MACD: A similar dynamic can be seen in the MACD, whose histogram remains very close to the neutral 0 level. This suggests balance in the average strength of short-term moving averages. This reading may also reflect relevant neutrality in short-term price movements.
Key levels:
1.15127 – Relevant resistance: This important high level coincides with a retracement area from previous weeks and also with the barrier formed by the 50-period moving average. Price movements attempting to break above this level could start to put the long bearish trend line at risk and open room for a more dominant buying bias over the coming weeks.
1.14253 – Near-term barrier: This level corresponds to the most relevant neutral area now. Price movements too close to this level could continue to highlight significant indecision and even open room for a possible short-term sideways range over the next few sessions.
1.12851 – Definitive support: This level is associated with a neutral area observed in May 2025 and now acts as the main support to watch. If price continues to move closer to this area, the selling bias would be reinforced and the possibility of an extension of the bearish trend line as the dominant chart structure over the coming weeks would increase.
Written by Julian Pineda, CFA, CMT – Market Analyst
Figma po vytvoření formace dvojitého dna na 16,80 USD a návratu nad 50denní EMA míří k rezistenci na 27,80 USD. Management očekává, že nadcházející výsledky ukážou pokračující růst byznysu v Q2.
Figma stock has staged a modest comeback in the past few days, moving from a record low of $16.80 to the current $23.65.
This rebound may continue in the coming weeks after the stock formed a double-bottom pattern and as its earnings report looms.
The daily chart shows that Figma’s tide is turning after months of falling. It formed a double-bottom pattern at $16.80, its lowest level in April and June this year. Its neckline was at $27.80, its highest point on June 1 this year.
The stock has now moved above the 50-day Exponential Moving Average (EMA), while the Relative Strength Index (RSI) has jumped to 61 from the year-to-date low of 17.83.
Therefore, the stock will likely continue rising in the near term, potentially to the key resistance at $27.80.
A move above that level will point to more gains, potentially to the Ultimate Resistance of the Murrey Math Lines of $31.25, which is about 35% above the current level.
Figma Inc. stock chart | Source: TradingView
Figma is a top player in the software industry, where it offers a platform that simplifies how companies design. It is used widely by companies of all sizes, including giants like Google, Airbnb, Atlassian, Microsoft, GitHub, and Duolingo.
Its stock initially jumped after its IPO last year and then started a strong downward trend, reaching a record low this year.
This retreat happened as investors dumped software companies in a process that has become known as the SaaSApocalypse. Other top software companies like Atlassian, Adobe, Autodesk, and ServiceNow have plunged.
In reality, however, Figma’s business has continued to grow as more companies have embraced its solution.
Its last financial results showed that its revenue jumped by 46% in Q1 to $333.4 million, higher than its previous guidance.
The company’s results showed that its business continued to attract clients despite the AI disruption. The number of companies paying over $10,000 jumped to 15,218 from 11,107 in the same period last year.
Those paying $100,000 and above jumped to 1,525 from 1,031. Notably, the company received an order from one hyperscaler that added 35,000 paid seats during the quarter.
Instead of being disrupted by AI, the company is using this technology to improve and monetize its solution. For example, it started to implement AI credit limits for all its customers in March, without experiencing any significant churn.
The management team expects that the upcoming earnings report will show that its business continued growing in Q2.
Its guidance is that its revenue will be between $348 million and $350 million, up by 40% YoY.
It expects its annual revenue to be between $1.422 billion and $1.428 billion, representing a 35% YoY growth. The real figure will likely be higher than that, as the management tends to be highly conservative.
Most analysts have a price target that is higher than the current one. Bank of America analysts have a target of $30, while Wells Fargo’s Michael Turrin has a target of $36.
Piper Sandler, Citigroup, and JPMorgan analysts have targets of above $30.
Figma does have some challenges. For example, competition continues to rise, with companies like Sketch and Adobe being major ones.
Also, it is still losing money, with its loss from operations rising to $137 million in the first quarter. Its valuation is still high, with its forward price-to-sales ratio rising to 7.7.
Wedbush výrazně zvýšil cílovou cenu pro Sandisk a čeká výnosy téměř 9 miliard USD a zisk na akcii nad 37,50 USD ve fiskálním 4. čtvrtletí. Firma tvrdí, že i to může podceňovat sílu byznysu.
Wedbush is making a bold call on memory chip maker Sandisk NASDAQ: SNDK. The firm aggressively raised its targets for revenue, earnings, and stock price, citing pricing trends and a high likelihood that management had underestimated the strength.
Sandisk Today
$1,736.40 +62.43 (+3.73%)
As of 10:11 AM Eastern
This is a fair market value price provided by Massive. Learn more.
52-Week Range$40.10▼
$2,354.39P/E Ratio60.33
Price Target$1,765.19
Wedbush hiked its revenue and earnings targets by quadruple-digit basis points, pushed both above consensus, and warned that even these aggressive moves may understate the company's strength.
Get Sandisk alerts:
As it stands, Wedbush sees revenue approaching $9 billion for the fiscal 4th quarter, earnings per share exceeding $37.50, and the strengths persisting into subsequent years.
The long-term forecast echoes one issued by SK hynix's NASDAQ: SKHY CEO, suggesting that memory chip market constraints will persist at least until 2028, as capacity ramps take time and demand is just that high.
As it stands, consensus forecasts suggest revenue of $8.33 billion and adjusted earnings per share of $34, representing more than 11,000% growth over the prior year.
Sandisk Stock Can Double in Price From HereSandisk Stock Forecast Today12-Month Stock Price Forecast:
$1,765.19
5.45% Upside
Moderate Buy
Based on 25 Analyst Ratings
Current Price$1,673.97High Forecast$3,250.00Average Forecast$1,765.19Low Forecast$235.00Sandisk Stock Forecast Details
Wedbush isn’t the only analyst doubling down on their Sandisk targets in early Q3. Analyst trends include increasing coverage, firming sentiment, a Moderate Buy consensus rating, an 84% Buy-side bias among 25 analysts tracked, and an uptrend in the consensus price target.
As aggressive as Wedbush’s 62% price target increase, its $2,000 forecast falls far short of the high-end range. Revisions in early July put this market in the $3,000 to $3,200 range, sufficient for nearly 100% upside from mid-July support targets. The likely outcome is that Sandisk’s upcoming earnings report will trigger another wave of upgrades and revisions, keeping the uptrend intact.
Institutional activity aligns with bullish analyst activity and the stock's price upswing. The group owns nearly 80% of the shares and has been buying at a rate of more than $2 per $1 over the trailing 12 months. While profit-taking was the highlight in Q2 2026, the group resumed accumulation in early Q3, underpinning market support in the $1,650 to $1,750 range. With this in play, investors can assume downside risk is limited ahead of the release. The risk is that the upcoming release will fall short of loftiest expectations, setting the stage for continued market consolidation.
The technical outlook is bullish. The SNDK market has been strengthening since the IPO, gained traction in late 2025, and has been in rally mode since. The story as of mid-July is that a near-term peak was reached and price correction ensued, setting up the pre-earnings opportunity. Signals, including MACD convergence, suggest the recent high will be at least retested and that higher highs are likely.
Why Is Sandisk Important to AI? Non-Volatile Memory StorageSandisk is important to AI because of memory. Its NAND Flash and solid-state drives provide permanent, non-volatile (not requiring power to retain data) memory storage critical to AI applications. While DRAM provides ultra-fast workspace directly connected to the processor, Sandisk products serve as the reservoir from which DRAM pulls the information it needs. Without it, there is no way to store the massive amounts of data being created, much less use it effectively. The takeaway is that Sandisk has transitioned from a legacy consumer brand that made flash drives to an AI-critical infrastructure provider with a custom suite of AI-enabling products.
Sandisk has three major catalysts this year that will mark milestones in its transition to AI infrastructure pure-play status. The first is the launch of high-bandwidth flash memory, intended to alleviate bottlenecks in data transfer within the data center. The first engineering samples are expected to ship later this year and are viewed as a validation achievement.
The second catalyst is locking in long-term contracts. Until now, memory was sold largely on a spot basis, but Sandisk is following industry suit, shifting to a more visible contract model—each design win equates to margin lock-in and reduced cyclicality, improving visibility for investors. The final catalyst is the upcoming release and guidance, expected to build on strengths revealed in the record-setting Q3 release.
Sandisk’s biggest risk is competition. The flash and NAND memory markets are highly competitive, with players like Samsung Electronics OTCMKTS: SSNLF commanding market share. The risk is that one of its competitors emerges with better technology, usurping the existing opportunity. The caveat is that demand dynamics suggest ample room for numerous players. Valuation is also a risk, with the stock trading at approximately 25x this year's earnings forecast, which reflects robust growth. Forecasts suggest the valuation falls as low as 8x as soon as next year.
Should You Invest $1,000 in Sandisk Right Now?Before you consider Sandisk, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sandisk wasn't on the list.
While Sandisk currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
A specially designed Google logo, during the opening of Google's new Artificial Intelligence (AI) centre in Berlin, Germany, March 5, 2026. REUTERS/Annegret Hilse/File Photo Purchase Licensing Rights, opens new tab
CompaniesBERLIN, July 14 (Reuters) - Germany's media regulator said on Tuesday that Google's AI Overviews and Perplexity AI are subject to the country's media laws, stepping up scrutiny of AI-generated content after a German court found Google liable for inaccurate information produced by the feature.
The Commission for Licensing and Supervision, ZAK, which represents Germany's 14 state media authorities, said AI-generated news summaries and chatbot responses constitute content created by the providers themselves rather than merely displaying third-party material.
Jumpstart your morning with the latest legal news delivered straight to your inbox from The Daily Docket newsletter. Sign up here.
The ruling follows increased scrutiny of AI-generated search summaries in Germany and elsewhere in Europe.
In a separate case, a court in Munich held that Google could be directly liable for allegedly false statements generated by its AI Overview feature, finding that AI-produced summaries amounted to the company's own content rather than a mere display of third-party information, according to German newspaper publishers' association BDZV.
"AI search engines and chatbots are content providers, and we will consistently apply German media law to them from now on," ZAK Chairman Thorsten Schmiege said in a statement.
The regulator said the liability exemption under the European Union's Digital Services Act, which generally shields platforms from responsibility for illegal user-generated content, did not apply in these cases.
According to the regulator, Google's AI Overviews are displayed prominently within search results, making traditional lists of links less visible and thereby unfairly disadvantaging third-party media content.
It also argued that chatbots such as Perplexity influence the discoverability of news content when they select and present sources, links or recommendations alongside AI-generated answers.
Such services could therefore qualify as media intermediaries and be subject to rules designed to safeguard media plurality.
Google said it planned to appeal the decision, which a spokesperson said "fails to recognise how people's preferences when searching for information and the information ecosystem are changing."
"Our AI-powered summaries enhance the search experience in Germany - they help users discover new content and ask follow-up questions," the spokesperson said.
Perplexity declined to comment on the decision but said it complies with the EU's privacy rules, or GDPR, and holds SOC 2 Type II security and privacy certification.
Reporting by Klaus Lauer, Writing by Friederike Heine, Editing by Louise Heavens
Our Standards: The Thomson Reuters Trust Principles., opens new tab
Nvidia by podle odhadů mohla do konce dekády výrazně růst, protože její adresovatelný trh v datových centrech může přesáhnout 1 bilion USD. Analytici zároveň čekají 88% nárůst zisku na akcii ve fiskálním roce 2027 (končícím v lednu 2027).
Shares of Nvidia (NVDA +0.42%) have risen by an impressive 380% over the past three years, fueled by the artificial intelligence (AI)-driven demand for its data center chips. However, the stock has been in a rut lately, rising just 12% in 2026, as of this writing.
The surprising thing to note here is that Nvidia stock is struggling to break out despite sustaining impressive revenue and earnings growth, driven by its continued dominance in the lucrative AI accelerator market. However, the world's largest company by market cap can easily step on the gas once again.
In fact, Nvidia could witness a solid increase in its stock price by the end of the decade. Let's see why that may be the case.
Image source: The Motley Fool.
Nvidia's massive addressable market points toward solid long-term growth Nvidia's foundry partner TSMC recently noted that the global semiconductor market's revenue could reach a whopping $1.5 trillion in 2030. The Taiwan-based foundry giant had previously anticipated $1 trillion in semiconductor revenue by the end of the decade. However, AI-fueled demand for chips led to a substantial upgrade to its guidance.
Today's Change
(
0.42
%) $
0.85
Current Price
$
204.38
TSMC points out that AI and high-performance computing (HPC) chips will account for 55% of this lucrative opportunity. That puts Nvidia's addressable opportunity in the AI data center chip market at an impressive $825 billion. For comparison, Nvidia's data center revenue in fiscal 2026 (which ended in January this year) was $193.7 billion.
It is worth noting that $162.3 billion of its fiscal 2026 data center revenue came from sales of compute chips, while the rest was from networking components. So, there is still a lot of room for Nvidia to boost its data center chip revenue over the next five years, especially considering that it is the dominant player in this market with an estimated 80% share.
However, analysts believe that Nvidia's AI data center chip market share may have peaked. That's not surprising, as competitors Advanced Micro Devices and Broadcom have been making solid strides in this space. Additionally, Nvidia's customers, which include both hyperscalers and pure-play AI companies, have been designing in-house chips to lower operating costs.
That's why Nvidia's AI chip market share is anticipated to decline to 75% this year. Let's assume Nvidia continues to lose ground in AI chips for the next four years and ends up at just 50% market share in 2030; it can still generate more than $400 billion in data center chip revenue in 2030 (based on the $825 billion market size estimated above).
That's almost 2.5x the data center compute revenue it generated in fiscal 2026. At the same time, investors shouldn't forget that Nvidia's data center networking revenue is growing at a much faster pace than compute. The company reported a 142% year-over-year increase in networking revenue in fiscal 2026 to $31.4 billion. It has started fiscal 2027 on a stronger note in this segment, with networking revenue tripling year-over-year to $14.8 billion.
Nvidia sells networking hardware, such as Ethernet and InfiniBand switches, and also offers software platforms to help developers program and manage networks. What's worth noting is that demand for these networking switches is increasing rapidly due to AI and HPC. The InfiniBand market, for instance, is expected to clock 36% annual growth over the next five years, according to Mordor Intelligence. It could generate more than $164 billion in revenue in 2031.
Meanwhile, the data center switch market is projected to exceed $100 billion in revenue by 2030, according to Dell'Oro Group. Ethernet switches are expected to dominate this space. The pace at which Nvidia's networking revenue is growing suggests the company is capturing a larger share of this space, which could pave the way for significant growth in this business segment over the next five years.
In all, Nvidia's data center addressable opportunity, including both networking and compute, could surpass $1 trillion by the end of the decade. That's why there has been a significant jump in Nvidia's consensus revenue growth projections through fiscal 2029.
Data by YCharts
The company's earnings growth potential suggests it can become a multibagger Nvidia's impressive top-line growth is all set to filter down to the bottom line. Analysts are projecting an 88% spike in Nvidia's earnings in fiscal 2027 (ending in January 2027) to $8.97 per share. This will be followed by robust double-digit growth over the next two fiscal years.
Data by YCharts
Assuming Nvidia's bottom line grows by even 15% a year in fiscal years 2030 and 2031, its earnings per share could reach $21.24 by the end of the decade (as its fiscal 2031 will end in January 2031). If this AI stock trades at 27 times earnings at that time (in line with the tech-laden Nasdaq-100 index's forward earnings multiple), its stock price could reach $573. That's almost 2.8x Nvidia's current stock price.
As Nvidia trades at just 24 times forward earnings, investors are getting a solid deal on this growth stock, which they should consider grabbing, given the potential upside it could deliver through 2030.
JPMorgan Chase & Co. (JPM - Free Report) came out with quarterly earnings of $6.14 per share, beating the Zacks Consensus Estimate of $5.59 per share. This compares to earnings of $4.96 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of +9.84%. A quarter ago, it was expected that this company would post earnings of $5.49 per share when it actually produced earnings of $5.94, delivering a surprise of +8.2%.
Over the last four quarters, the company has surpassed consensus EPS estimates four times.
JPMorgan Chase & Co., which belongs to the Zacks Financial - Investment Bank industry, posted revenues of $57.35 billion for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 16.70%. This compares to year-ago revenues of $44.91 billion. The company has topped consensus revenue estimates four times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
JPMorgan Chase & Co. shares have added about 3.8% since the beginning of the year versus the S&P 500's gain of 9.8%.
What's Next for JPMorgan Chase & Co.?While JPMorgan Chase & Co. has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for JPMorgan Chase & Co. was favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $5.50 on $48.72 billion in revenues for the coming quarter and $22.82 on $197.22 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Financial - Investment Bank is currently in the top 29% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
BGC Group (BGC - Free Report) , another stock in the same industry, has yet to report results for the quarter ended June 2026. The results are expected to be released on July 30.
This brokerage company is expected to post quarterly earnings of $0.34 per share in its upcoming report, which represents a year-over-year change of +9.7%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
BGC Group's revenues are expected to be $814.9 million, up 3.9% from the year-ago quarter.
